A cross-disciplinary view of testing and bioinformatic analysis of SARS-CoV-2 and other human respiratory viruses in pandemic settings by Hossain, MA et al.
 
 Date of publication xxxx 00, 0000, date of current version xxxx 00, 0000. 
Digital Object Identifier 10.1109/ACCESS.2017.Doi Number 
A cross-disciplinary view of testing and 
bioinformatic analysis of SARS-CoV-2 and 
other human respiratory viruses in pandemic 
settings 
Md Arafat Hossain1, (Member, IEEE), Barbara Brito-Rodriguez2, Lisa M Sedger3, and  
John Canning4, (Member, IEEE) 
1Department of Electrical and Electronic Engineering, Khulna University of Engineering & Technology, Khulna 9203, Bangladesh 
2i3 Institute, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia 
3Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia 
4interdisciplinary Photonic Laboratories (iPL), University of Technology Sydney, NSW 2007 & The School of Chemistry, The University of Sydney, 
NSW 2006, Australia 
Corresponding author: Md Arafat Hossain (e-mail: arafat@eee.kuet.ac.bd). 
 
ABSTRACT The SARS-Coronavirus-2 (SARS-CoV-2) infectious disease, COVID-19, has spread rapidly, 
resulting in a global pandemic with significant mortality. The combination of early diagnosis via rapid 
screening, contact tracing, social distancing and quarantine has helped to control the pandemic. The absence 
of real time response and diagnosis is a crucial technology shortfall and is a key reason why current contact 
tracing methods are inadequate to control spread. In contrast, current information technology combined 
with a new generation of near-real time tests offers consumer-engaged smartphone-based “lab-in-a-phone” 
internet-of-things (IoT) connected devices that provide increased pandemic monitoring. This review brings 
together key aspects required to create an entire global diagnostic ecosystem. Cross-disciplinary 
understanding and integration of both mechanisms and technologies for effective detection, incidence 
mapping and disease containment in near real-time is summarized. Available measures to monitor and/or 
sterilize surfaces, next-generation laboratory and smartphone-based diagnostic approaches can be brought 
together and networked for instant global monitoring that informs Public Health policy. Cloud-based 
analysis enabling real-time mapping will enable future pandemic control, drive the suppression and 
elimination of disease spread, saving millions of lives globally. A new paradigm is introduced – scaled and 
multiple diagnostics for mapping and spreading of a pandemic rather than traditional accumulation of 
individual measurements. This can do away with the need for ultra-precise and ultra-accurate analysis by 
taking mass measurements that can relax tolerances and build resilience through networked analytics and 
informatics, the basis for novel swarm diagnostics. These include addressing ethical standards, local, 
national and international collaborative engagement, multidisciplinary and analytical measurements and 
standards, and data handling and storage protocols. 
INDEX TERMS - Antibody test, antigen test, bioinformatics, COVID-19, internet-of-things, lab-in-a-
phone, LAMP test, point-of-care test, PCR, SARS-CoV. 
I. INTRODUCTION 
A novel respiratory disease caused by the severe acute 
respiratory syndrome Coronavirus-2 (SARS-CoV-2) was 
first reported in Wuhan China, in December 2019 [1]. It was 
defined by the World Health Organization (WHO) as 
“coronavirus infectious disease of 2019” or COVID-19 [2]. 
SARS-CoV-2 virus spread quickly within China and 
internationally creating a global pandemic: by November 
2021, WHO estimates that at least 263 million people 
worldwide have been infected [2]. This markedly contrasts 
with other human coronaviruses that circulate frequently in 
humans causing upper respiratory tract infection but with 
milder symptoms [3]. SARS-CoV-2 infects upper and lower 
          M. A. Hossain et al: Rapid Testing & Bioinformatic Analysis of SARS-CoV-2 and Human Respiratory Viruses in Pandemics 
2 
 
respiratory tract tissues and further spreads to other tissues 
generating diverse pathologies. Systemic inflammatory 
immune responses is frequently observed where high levels 
of inflammatory cytokines, known as a cytokine storm, are 
generated [4]. Thus, the pathobiology of SARS-CoV-2 
infection is complex. Blood clotting events also occur, and 
there are reports of an autoimmune response in infected 
children that resembles Kawasaki disease [5]. Since the virus 
has been spreading through a naïve immune system, the 
infection has evolved and changed over time. Initially 
COVID-19 was particularly virulent in people over 50 years 
of age, especially in males [6]. However, more recent 
variants are increasingly infectious and virulent in younger 
people [7]. For example, the delta and omicron variants are 
estimated to be several times more infectious than the virus 
found originally in Wuhan. Fortunately, optimal treatments 
in different patient cohorts are resulting in higher survival 
rates. 
 
An understanding of the major transmission mechanisms 
of SARS-CoV-2 has helped to mandate partially effective 
infection control measures. The virus is primarily spread by 
respiratory droplet and aerosol particles [8], leading to 
recommendations for health care workers to use N95 masks, 
and for general masking, social distancing and home 
quarantine for the wider population. The sustainability of the 
SARS-CoV-2 virus on surfaces, impacts on the choice of 
control measures being implemented. Nevertheless, studies 
investigating the likely origins of the SARS-CoV-2 are based 
primarily on nucleic acid homology. These show high 
similarity with existing bat coronaviruses suggestive of a 
spill-over event from bats to humans and/or through an 
intermediate animal species [9-11]. The nature of this 
spillover event is highly contested. 
 
Traditional laboratory-based diagnostics such as reverse 
transcriptase-polymerase chain reaction (RT-PCR) 
generally offers accurate results. However, they require 
specific equipment, laboratory expertise and time to 
perform to confirm positive results. Unfortunately, rapid 
accurate diagnostic tests for COVID-19 underpin the 
success of viral pandemic infection control measures. In 
Europe, the US and Singapore, rapid diagnostic COVID-19 
tests are therefore widely deployed to help detect the virus 
and control transmission through infected individuals. For 
various reasons, other countries have been more cautious in 
the use of rapid-testing devices. Despite reticence over 
accuracy and other factors, real-time (rapid) diagnostics for 
SARS-CoV-2 virus detection are the first stage of a new 
future paradigm of interconnected diagnostic mapping to 
detect and contain pandemics in near to real-time. Coupled 
with ubiquitous consumer technologies, such as 
smartphones-based technologies, the development and 
integration of novel biosensors, permits high speed wireless 
connectivity for globally interconnected infectious disease 
incidence monitoring. 
Rapid detection tests for SARS-CoV-2 are increasingly 
available globally (for reviews see [12-16]). Whilst existing 
literature focuses largely on traditional laboratory-based 
nucleic acid- or antibody-based COVID-19 tests, with 
various modifications, there has been alternative advances 
that can offer faster response and wider connectivity. These 
include surface and wearable sensor technologies, and lab-
in-a-phone type platforms, that together with network 
diagnostics such as cloud-based informatics, creates a 
much-improved global monitoring capability. Here, we 
provide a cross-disciplinary review of current technologies, 
bridging the gap between biomedical technologies and IoT 
engineering. This review will: (1) discuss the major 
mechanisms of SARS-CoV-2 transmission, highlighting the 
important role of water and its impact on  viral spread and 
detection, (2) review the range of detection and diagnostics 
platforms available as point-of-care (POC) tests (for 
clinicians), (3) describe the main smartphone-based “lab-
on-a-phone” technologies that can read and analyse POC 
tests, and (4) discuss the integration of networked field 
diagnostics where millions of smartphone instruments can 
be interconnected for enhanced instant and resilient health 
informatics for detection, mapping and containment of 
pandemic pathogens. The concept of novel super 
instruments based on swarm diagnostics is described. 
Finally, we draw attention to issues raised by such 
interconnected technologies including ethics around patient 
information, privacy rights and confidentiality of test result 
data and its use locally and globally.  
 
 
II. TESTING IN THE CONTEXT OF RESPIRATORY 
VIRUS TRANSMISSION 
The estimated total number of COVID-19 cases is always 
dependent on, one, testing rates and, two, the percentage of 
both symptomatic and asymptomatic infected people being 
tested. For example, asymptomatic people are less likely to 
be submitting themselves for testing despite being 
infectious because they are unlikely to consider themselves 
infected when any symptom is mild. The incubation period 
for SARS-CoV-2 to produce symptoms of COVID-19 are 
usually 4-5 days from the date of infection, but 
asymptomatic infection can start earlier and extend as much 
as 14 days or more. Nevertheless, up to this point 97.5% of 
those who experience symptoms tend to do so within 11.5 
days of infection [17, 18] and many well before this.  
 
Any test can yield a false negative test result (albeit often 
at very low rates) and some infected individuals remain 
asymptomatic and/or harbour very low levels of virus that 
are below the detection limit for several days post-infection 
[19]. Each of these situations permits infectious people to 
continue to spread the virus. In the context of a pandemic, 
the factors that influence viral spread include both the 
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nature of the infective agent (in this case an RNA virus) and 
the environment it occupies. For example, indoor/outdoor 
air in various moisture levels, on different surface types, 
before or after surface cleaning, all factors that directly 
influence infectious transmission. 
A. WATER VAPOUR, DROPLETS AND AEROSOLS – 
THE ROLE OF WATER 
Emitted airborne water such as atmospheric droplets are 
relatively large and generally fall to the ground or onto 
surfaces within 2 m where they can survive on surfaces for 
several days or longer [20]. “Physical distancing” aims to 
avoid exposure to these infectious droplets. Regular hand 
washing and wearing masks is also an effective (though not 
100 %) measure that reduces droplet-based infection arising 
from surface fomites and aerosol. The practical effectiveness 
of distancing and masking tends to wane once the pandemic 
is perceived as non-serious or being “under control” and 
complacency sets in. Importantly, smaller droplets or 
aerosols are < 1 µm in size and present in human breath – for 
the recent delta strain this has become the main vector of 
transmission requiring that both effective masking and 
distancing be rigidly maintained. 
 
Aerosols are spherical due to the surface tension that arises 
from the dipole alignment of water, both actual and 
instantaneous (or van der Waals), on the droplet surface. This 
creates a quasi-self-aligned charge-resistant surface that 
resists evaporation and extends the drop lifetime. 
Consequently, aerosols can be transmitted well beyond 2 m, 
presenting an almost intractable challenge – for example, 
passing infected joggers can potentially infect dozens of 
people with an aerosol reach of tens of meters even outdoors. 
SARS-CoV-2 is capable of aerosol spread, particularly the 
delta variant [21]. One approach to combat this in buildings 
is to ensure sufficient ventilation, dispersing and accelerating 
drying of the aerosol droplet. Once the water content is 
removed, the membrane-enveloped virus is generally 
denatured or rendered inactive. The spike proteins used for 
attachment to cells have protruding proteins that may be lost 
(together with the lipid membrane) or rendered non-
functional by virtue of the structural impact of dipole 
dehydration. UV irradiation can also disrupt the virus in the 
droplets [14], a factor that may explain why viral spread in 
Australia has been noticeably low despite huge congregations 
of complacent individuals at beaches. 
 
A respiratory virus particle can be present both within 
water droplets and in or on aerosols – depending on its 
charge. It is not known whether the virus can survive for 
longer within the droplet, or on the surface of the droplet but 
an air-water interface is charged differently to the droplet 
interior surface interface [22]. Other component substances 
such as mucus means that the drop is never actually an 
“idealized” water drop, but a complex drop, with variable 
properties that affect droplet lifetimes and drop size. 
Additional lifetime factors include rapid drying of a surface 
that accelerates droplet denaturing, or humidity that will 
prolong droplet longevity and virus viability. In this regard, 
factors are being considered that alter the interaction of the 
virus particle with the epithelium. Certain molecules such as 
carrageenan can be produced in nasal sprays to inhibit 
droplets from attaching to the nasal passageway by virtue of 
mimicking cell surface heparan sulphate proteoglycans. 
Clinical trials are currently assessing if carrageenan-based 
nasal and throat sprays reduce SARS-CoV-2 infection in at-
risk health care workers [23]. Similarly, hypromellose 
(hydroxypropylmethylcellulose) has been used for the 
controlled delivery of hydrophilic drug materials [24] and is 
also being considered for its potential to inhibit SARS-CoV-
2 [25]. 
 
Whether in droplets, or aerosols, masks function to protect 
from respiratory spread viruses. Masks should ideally be 
comprised of three layers. The innermost layer limits 
expelled virus (from the infected person) where electret 
generation draws water away from the surfaces and helps to 
capture smaller drops that might otherwise pass through the 
mask pores, trapping some of this at the inner layer. The 
outer layer acts as a hydrophobic surface repellent (after 
charging its electrostatic surface – similarly exploiting the 
attraction/repulsion of the aerosol’s charge). Thus, masks 
reduce the potential reception of virus-laden droplets by the 
receiver. There is also potential to add antiviral disinfectants 
within the central layers to disrupt the viral material and 
render it uninfectious [26]. 
B. SURFACE SPREAD OF FOMITES 
Contaminated surfaces occur where water droplets or 
aerosols reach surfaces. Depending on whether a surface is 
hydrophilic or hydrophobic, a virus that is present within 
water vapour is deposited onto the surface. Viruses only 
replicate within an infected host cell (in this case a human or 
animal cells) but can exist, without replicating, on a surface 
for days or longer [20]. As surfaces differ, so too does the 
potential for long- or short-term virus livability. For example, 
smooth solid surfaces such as stainless steel, glass or clear 
plastic face shields have different hydrophobic and 
hydrophilic properties to rough surfaces. At its simplest, this 
impacts the droplet drying rate and therefore the survivability 
of the virus particle. 
 
Water assembly processes at the surface-water interface 
and van der Waals electrostatic binding are factors that 
determine the longevity of a water droplet or aerosol on that 
surface. In fact, water molecules can form stable atomic level 
interfacial surface layers and exist there for long periods, 
even days, at room temperature, well after the bulk of the 
droplet has evaporated [27]. However, these water layers can 
be rapidly removed by heating to ~ 40 °C [22], faster at 70 
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°C [28]. Therefore, high temperature industrial blow dryers 
could be used to both quickly dry and denature viruses that 
are present on surfaces, preventing spread of the aerosol. An 
alternative approach is to treat the surface to attract water 
droplets, further spreading them over the surface, or within a 
porous surface coating, to aid drying. Drying quickly 
denatures the virus on the surface. The addition of an 
antiviral or antibiotic disinfectant to a surface coating can 
render the virus quickly uninfectious to human cells. Mini 
protein domain reagents could even theoretically be used as a 
viral attractant trap, especially on critical surfaces such as 
stainless-steel hospital door handles. A consideration is 
ensuring potency of the disinfectant layer after repeated 
surface cleaning. Nevertheless, several different protein 
micro-domain attractors could be combined together in a 
single application mixture for absorption and denaturation of 
different human respiratory-spread viruses. 
 
Although this review focuses on respiratory viruses, both 
SARS-CoV-1 and -2 infected humans also shed virus in their 
faeces [6]. Hence faecal derived droplet/aerosols provide an 
avenue for fomite-based human-human transmission of the 
virus [29]. This was evident in the earlier SARS-CoV-1 
outbreak, where aerosolized virus-contaminated faecal 
content permitted the spread of the virus within the Amoy 
Gardens high-rise apartments in Hong Kong. Plumbing 
designs and engineering for the use of a water trap 
(disconnecting the continuity of the sewage drainage and 
floor drain systems) prevents faecal-aerosol spread of viruses 
[30]. The faecal presence of virus includes both infectious 
viral and viral remnants. In Australia, and other places 
around the world, sewage surveillance is used to identify 
community persistence of the virus, even amidst a period 
when zero daily new cases are recorded [31]. Indeed, sewage 
detection of the virus can be the first indicator of the spread 
of infections of coronaviruses within a new community 
population.  
III. DIAGNOSTICS 
In considering detection of pandemic spread of a respiratory 
pathogen, particularly viruses, one must understand the 
methods of viral testing and surveillance. The next section 
reviews the principles of laboratory and point-of care (POC) 
detection testing for human respiratory viruses, focusing 
particularly on SAR-CoV-2 and new detection technologies. 
 
A.  VIRUS NUCLEIC ACID TESTS 
Nucleic acid tests directly detect the presence of a virus 
genome: either DNA or RNA. For SARS-CoV-2, or 
influenza viruses the genomes are RNA, which can easily be 
extracted from respiratory secretions collected on 
nasopharyngeal and throat swabs (Fig 1A and B) [32]. The 
samples are analyzed using three main methods: 
 
1) POLYMERASE CHAIN REACTION (PCR) 
A standard PCR assay copies and amplifies the nucleic acid 
and is the “gold standard” for virus detection. For RNA 
viruses, the process starts with a reverse transcription 
reaction; a test step that converts a single strand of extracted 
viral genome RNA into a complimentary sequence of single 
stranded DNA (ssDNA). The DNA template is amplified 
generating a double stranded DNA (dsDNA) PCR product 
(Fig 1C). In PCR, repeated iterations, amplify the cDNA up 
to 240 times (using 40 or more cycles) producing high yields 
of the cDNA PCR product, that are visualized by fluorescent 
intercalating dyes or fluorescently-conjugated DNA 
sequence-specific oligonucleotide probes [33, 34]. For each 
PCR “cycle”, a temperature of T = 95 °C denaturing step is 
followed by oligonucleotide primer annealing step of T = 50-
60 °C. Here, the viral sequence specific DNA oligomer 
anneals to the targeted genome sequence and the viral nucleic 
acid is amplified by a DNA polymerase. The PCR product – 
a cDNA copy of the segment of viral genome template - can 
then be sequenced (if required). By repeating the PCR 
cycling process up to 40 times, logarithmic amplification 
leads to high sensitivity. The primer sequences confer high 
test specificity whilst the fluorescence can provide 
quantitative estimates of viral load. 
 
PCR tests require skilled laboratory scientists and a 
thermal cycler (equipment). In times of pandemic spread of 
the virus, the PCR detection test rates must be high in order 
to provide useful community-level information about 
infection incidence. To address this in practice, patient 
samples are routinely pooled (usually 5-10 patient 
samples/pool) and the PCR is run on the pooled sample. 
Confirmation of a positive result is then achieved by first re-
extracting the nucleic acid from the individual patient 
samples, and usually between 3-5 separate PCRs are then 
performed – repeating the original sequence-specific PCR, as 
well performing several other sequence-specific PCRs 
(targeting other viral genome segments). Thus, a true positive 
result is determined based on the positive detection of a 
minimum of 3 positive PCRs of viral nucleic acid [34]. A 
negative PCR reaction without any extracted viral nucleic 
acid is always included in the test run because this confirms 
that a positive reaction is not due to reagent contamination. 
However, the obvious limitation to PCR testing is the need 
for the virus-nucleic acid specific oligonucleotide primers, 
and hence the virus must first be characterized to some 
extent, such that the virus genome, or a partial sequence of it, 
is determined a priori. Thus, metagenomics nucleic acid 
sequence is first obtained with random primers and the 
overlapping sequences assembled.  
 
A range of commercially available RT-PCR test kits are 
currently available all human respiratory viruses: adenovirus, 
coronavirus SARS-CoV-2 and influenza, respiratory 
syncytial virus and rhinovirus. In practice, however, when a 
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FIGURE 1.  Schematic of current diagnostic methods for viral nucleic acid detection. (A) Sampling from suspected cases or patients produces the test 
specimen. (B) Test samples and the structure of the SARS-CoV-2 virus. (C) Mechanisms of the COVID-19 diagnosis using nucleic acid-based tests: RT-PCR, RT-
LAMP & the CRISPR (SHERLOCK) systems. 
 
new virus emerges the PCR test is developed “in house” 
within a clinical microbiology laboratory and the primer 
sequences quickly shared internationally, rapidly establishing 
a standardized nucleic acid detection assay. 
 
2)  LOOP-MEDIATED ISOTHERMAL AMPLIFICATION 
(LAMP) 
An adaptation of the standard PCR assay is the LAMP 
method that amplifies the viral nucleic acid at a constant 
temperature (removing the need for a thermocycler) (Fig 1C). 
LAMP uses DNA polymerase with high strand displacement 
and replication activity, and two “inner” primers and “outer” 
primers that each recognizes separate regions on the target 
nucleic acid. The LAMP reaction is complete when all 
primers are correctly annealed to the template, achieving a 
high specificity reaction, reportedly with a low rate of false 
positive results [35]. Of note, the amount of DNA produced 
in LAMP reactions is higher than many conventional PCR 
reactions and the results can be visible to the naked eye [36-
38]. The detection sensitivity is improved by a customized 
chip to integrate rapid nucleic acid extraction based on an 
immiscible phase filtration method assisted by surface 
tension and digital isothermal amplification [39]. 
 
3)  CRISPR-BASED SHERLOCK SYSTEM 
Another molecular viral nucleic acid detection method 
utilizes the clustered, regularly interspaced, short palindromic 
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repeats (CRISPR) family of enzymes, such as Cas9, Cas12 
and Cas13. Such methods are already adapted for the 
detection of SARS-CoV-2 nucleic acid [40, 41]. This method 
relies on the endonuclease activity of the CRISPR enzyme 
after it binds to a specific target RNA via a guiding 
(programmable) RNA. The release of a reporter molecule 
yields a detectable signal – providing utility as a diagnostic. 
Specific high-sensitivity enzymatic reporter unlocking or 
“SHERLOCK” is one such assay (Fig. 3), reportedly 
achieving attomolar sensitivity and single-based mismatched 
nucleic acid specificity [42] – of significant benefit when 
strain (mutation) based discrimination is required.  Moreover, 
this assay can be read using a dipstick with the result 
generated within 40 minutes [43]. Recently, SARS-CoV-2 
was detected from CRISPR-Cas13a assay of nasal swab 
RNA and read using a smartphone microscope [44].   
B. NUCLEIC ACID ANALYSIS, BIOINFORMATICS & 
GLOBAL SURVEILLANCE OF PANDEMICS 
Next generation sequencing (NGS) platforms permit high-
depth sequencing of nucleic acid and short-read sequencing 
technologies have high throughput and high-cost efficiency. 
Illumina sequencing platforms rely on massive parallel 
sequencing of short DNA strands on a flow cell surface, 
where they are first amplified in clusters. The cluster is 
sequenced using reversible fluorescent dye terminators, 
where the fluorescent signal is emitted at each cycle – 
determining the nucleotide base (or ‘sequencing by 
synthesis’). At the beginning of an epidemic, “shot-gun 
metagenomics” can be used to identify the presence of an 
unexpected or novel microorganism by sequencing its 
genetic material; i.e. using samples from patient(s) with a 
characteristic disease of unknown cause (Fig 2A). Hence, 
fragmenting the DNA (or RNA) present in a sample and 
sequencing it reveals new, previously unknown, nucleic acid 
sequence. This approach was used to determine the SARS-
CoV-2 RNA virus genome sequence in samples taken from 
patients with pneumonia in Wuhan, China, in December 
2019 [45, 46]. The same approach has been used 
internationally to sequence viruses from bats and diverse 
wildlife species, in an attempt to understand the potential 
origins of SARS-CoV-1 and SAR-CoV-2 pandemics [47-49]. 
Although the output from NGS sequencing are short 
sequence data “reads”, these are easily “assembled” by virtue 
of their overlapping sequences elements, meaning the data 
can be used to generate a contiguous (“contigs”) viral 
genome sequence. When new viruses emerge, the taxonomic 
classification and viral identification is based on this nucleic 
acid sequence information (Fig 2A). A known “reference” 
sequence is quickly established, that can be directly 
compared to the genome sequences of viruses detected in 
patients in any country (Fig 2B).  
 
Directed, or targeted, genome sequencing approaches are 
more frequently used in the settings of national or global 
pandemics because they are considerably more efficient. In 
fact, in shot-gun metagenomics only a very small fraction of 
the sequenced nucleic acid in a sample belong to viral 
genomes. Most is the host cell nucleic acid and non-viral in 
origin. Therefore, once the viral sequence is known, targeted 
sequencing is used because only the viral nucleic acid is 
sequenced, permitting higher throughput.  
 
NGS sequencing provides information about the evolution 
of the virus in SARS-CoV-2 coronavirus-naïve human 
populations. Sequence information is shared through 
centralized repositories such as NCBI GenBank or GISAID 
[50, 51]. (GISAID currently has >4.545M SARS-CoV-2 
sequences as at October 24, 2021) (Fig 3A). The results then 
help Public Health decision-making that are implemented a 
health control measures. Thus, this type of sequence 
information can determine the index cases during specific 
local outbreaks, and the epidemiological spread of a specific 
stain of the virus. In Australia, for example, SARS-CoV-2 
sequence data from local community transmission was linked 
to imported cases in quarantine hotels which directly led to a 
review of the containment protocols to better prevent 
community spread of incoming international strains. 
 
The main value of genomic analyses of viruses is that it 
can reveal the molecular basis of emergence (and 
dominance) of virus variants [52]. Whilst the factors driving 
variant emergence remain a separate virological issue, the 
impact of variants ranges from potential immune escape 
(including a vaccine escape mutation), enhanced virulence, 
increased capacity for infectious spread or the development 
of resistance to an anti-viral drug. Viral variants emerge 
because viruses are inherently highly replicating organisms 
and replication of the genome is sometimes imprecise. Thus, 
genetic evolution of viruses occurs quickly, and the extend of 
evolution and spread is shaped by multiple host and 
environmental factors such as immune response competency 
and vaccination status. A UK viral variant, initially known as 
B.1.1.7 but now referred to as the ‘alpha’ variant, was first 
flagged in December of 2020 as a being “more fit” virus after 
observing that its frequency was rising much faster than other 
viral lineages [53]. Similarly, the delta variant is more 
transmissible (infectious), whereby only fleeting contact is 
required for human-human transmission. As a consequence, 
many countries are tightening public health measures based 
on detecting this variant within a community outbreak [7] 
and global access to this information can direct the option to 
change vaccine virus strain formulation, if/when required. 
 
C.  ANTIBODY TESTS 
“Antibody tests” provide evidence of current versus prior 
infection by detecting the presence of antibody molecules in 
the blood. An antibody, also technically known as an 
immunoglobulin (Ig) molecule, is a multi-chain protein 
comprised of two heavy chains and two smaller or light  




     
FIGURE 2. Next generation sequencing technologies applications during the SARS-CoV-2 pandemic. A. Metagenomics approaches used at the beginning 
of the SARS-CoV-2 epidemic to investigate the causal agent of a cluster of “novel” pneumonia cases, in Wuhan, China. Extraction of nucleic acid, fragmenting 
and amplifying the nucleic acid fragments, then adding “adaptors” that permit the fragments bind to a flow cell in the NGS platform. All fragments are sequenced in 
parallel, and detected by different fluorescent signals emitted by the four nucleotides: A, T, G, C. The sequence for all fragments is assembled to generate a 
contiguous “reference” sequence. The sequences are then queried against existing reference databases. This permits the taxonomic classification and 
identification of genomic species. B. Whole genome sequence of SARS-CoV-2 also begins with nucleic acid extractions, then amplifying selected targeted 
genome regions with specific oligonucleotide primers that bind to overlapping regions of the viral genome. This PCR product is sequenced in the flow cell. 
Because SARS-CoV-2 genomes are similar, the assembly is guided by mapping all the sequenced reads to a reference sequence. A consensus of these 
references is then obtained as one linear sequence from a patient’s sample. 
 
chains. The combined heavy and light chain region binds to 
an “antigens” with high specificity and high affinity. Other 
regions with the antibody molecule mediate several effector 
functions such as binding to Fc-receptors highly expressed 
by phagocytic macrophages and natural killer cells that 
facilitate removal or killing of virus infected cells. When a B 
lymphocyte produces an antibody, it first produces an IgM- 
antibody. It then changes its heavy chain to create another 
antibody molecule, an IgG, with the same specificity to the 
viral antigen – a process known as “isotype switching”. 
Hence, the antibody affinity is increased, and new Fc-
dependent effector functions are gained whilst retaining 
specificity. Detection of only IgM tends to indicate a current 
infection, whereas the detection of IgG only (and low or no 
IgM) indicates a more distant or past infection. 
 
Antibody molecules are soluble molecules present in the 
plasma component of blood and are readily detected by an 
enzyme-linked immunosorbent assay (ELISA). In this assay 
a purified protein is bound to the wells of a 96-well flat 
bottom plastic dish. A “blocking” step using fat milk or 
bovine serum albumin is employed to bind to any residual 
plastic surfaces not already covered by the antigen. If any 
virus-specific antibodies are present in-patient plasma they 
will bind to the antigen (present on the wells of the dish).  
Bound plasma antibodies are detected via the use of another 
or “second” antibody with specificity to the type of human 
Ig; i.e. IgM or IgG. The detection antibody is chemically 
conjugated to an enzyme, whereby provision of the enzyme 
substrate permits a color reaction. Results are reported as 
positive (color) and negative (no color), but if serum 
dilutions are assayed, then the amount of antibody titre  




FIGURE 3. Uses of viral genetic sequence data. With the thousands of sequences obtained globally, phylogenetic trees are constructed to understand the 
evolutionary relationship of the viral genomes. When integrating this information with the epidemiological data (for example, the sample’s location of origin and day in 
which the sample is collected) maps that illustrate the virus spread and evolution can be generated. Tracking new lineages or sequence variants (viruses that are 
genetically related and that group in a branch of the phylogenetic tree) can help the early detection of a potentially highly transmissible or more virulent form of the virus. 
For example, the specific changes in a viral spike protein sequence can be monitored - the spike protein is the viral surface protein engages with a host cell receptor 
molecule. The viral spike is recognized by the host immune system antibodies that confer immunity. Therefore, tracking changes in the spike protein sequence 
identifies the evolution of the virus with respect to its antigenic properties and even the capacity of vaccines to confer immunity – protection capability. The phylogenetic 
tree in the image was constructed using 200 random samples from GISAID database, IQ-TREE [54] with the GTR + F + R2 substitution model. The map was created 
in QGIS [55] and the genome map was created using SnapGene [56].  
 
yielding a positive result is quantitated by reading color 
intensity spectrophotometrically. Carefully performed, 
ELISA assays can demonstrate an increase or decrease in the 
amount of a pathogen-specific IgM and IgG thereby 
providing a temporal indictor or “infection clock”. Antibody 
testing therefore identifies people who have been infected but 
already recovered from COVID-19, by detecting the 
presence of virus-specific antibodies. These individuals may 
be eligible to donate their blood for clinical use as 
convalescent plasma to treat others with severe life-
threatening   disease [57, 58]. If required, ELISAs can be 
used to evaluate vaccine effectiveness by detecting the 
vaccine induced virus-specific antibody. Importantly, an 
antibody test determines the true number of cases and extent 
of a pandemic spread because it also identifies asymptotic 
cases [59]. Antibody-based tests have been developed as 
point-of care (POC) items for consumer use and are already 
available for the diagnosis of pandemic or seasonal viruses 
such as influenza and SARS-CoV-2 [60, 61]. Below, the 
current range of antibody-based POC devices and their utility 
with smartphone-connectivity are summarized. 
 
1) LATERAL FLOW TEST DEVICES 
Like an ELISA, a lateral flow test device detects the presence 
of antibodies in plasma. It uses a paper-like membrane strip 
usually coated with two-lines. For example, gold 
nanoparticle-conjugates are present in one line and capture 
antibodies in the other line [62]. The patient’s plasma is 
drawn with capillary action across the strip (Fig 4A) and as 
the sample diffuses past the first line, the antibodies bind to 
the gold nanoparticles and the conjugate flows through the 
membrane. As it reaches the second line, the conjugate is 
immobilized by the enzyme-conjugated capture antibodies, 
and the line becomes visible after substrate is produced. 
Individual gold nanoparticles are red, but a solution 
containing clustered gold nanoparticles is blue (due to 
coupling of the plasmon bands). Appearance of the color 
indicates a positive test, while an additional color line 
(control line) confirms the validity of the test (Fig 4A & B). 
These assays are only semi-quantitative as determined by the 
color intensity. The main disadvantage is operator variability: 
a color-blind person could find distinguishing the color 
difficult and the test is unusable by a blind person. However, 
the test is ideally amenable to smartphone analysis (removing 
this operator variability). Lateral flow “rapid diagnostic tests” 
(RDT) can be performed under 30 minutes. Nearly 40% of 
all the FDA-approved antibody tests developed within the 
first six months of the SARS-CoV-2 pandemic are rapid 
antibody tests [63]. More importantly, these type of test 
results are highly concordant with laboratory ELISA assays 
[64, 65].  
 
Smartphone-based lateral flow device detection methods 
already exist (Fig 4C) that enable instant communication of 
test results to Public Health officials and rapid global data 
collation via cloud-based systems [66-68] (see Section V). 
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This permits rapid deployment of health measures to targeted 
areas. The value of these technological capabilities are 
immense in rural areas were scientific laboratories may be 
absent or extremely distant from the source of the outbreak. 
 
2) MICROFLUIDICS ASSAYS 
In a microfluidic device, the color is produced in a reflecting 
path on a transparent substrate to improve signal-to-noise 
levels. Some complex microfluidic structures make use of 
3D-printable transparent polymers such as polymethyl 
methacrylate (PMMA) [69]. The digital assay applies an 
electromagnetic field to manipulate and mix individual 
droplets on a superhydrophobic plate (reducing the risk of 
physical contamination). For low-cost and flexible operation 
outside of the laboratory, paper-based analytical devices can 
be more suitable than polymer-based microfluidic chips [70]. 
Multiplexed detection of antibody response from different 
antigens of SARS-CoV-2 has been achieved with 
microfluidic POC tests [71]. 
 
Issues of false-positive or false-negative test rates remain, 
with the primary disadvantage being related to sensitivity of 
the small sample quantity being tested. This small volume 
confers several limitations. For example, when a low virus 
(antigen) sample is loaded, the antibody detection molecule 
may never interact with it. Also, if allowed to “float” within 
the sample chamber, there is a statistical hit and miss ratio 
that worsens with decreasing concentrations or with 
increased volumes. Issues of sensitivity are addressed by 
amplifying the signal using fluorescence and 
chemiluminescence [75, 76], but these require excitation 
from laser or broad-spectrum light. Although detection 
requires an excitation light source, an emission filter, and 
photodiode or CMOS chip, highly-sensitive tests have been 
developed for the fluorogenic detection of antibodies specific 
to zika virus (ZIKV), chikungunya virus, and dengue virus 
(DENV) using a two-stage LAMP-based microfluidic nucleic 
acid detection [72]. The limit of detection is currently at the 
level of single copy of nucleic acid in PBS and 10 copies of 
viral genetic material  in human serum and the sensitivity can 
be increased by using 3D membrane filters capable of rapid 
and multi-fold analyte capture  [72], or simply delivering 
more capture antibody. Electrochemical biosensors are also 
being developed that produce an electrical signal or an 
optical emission (electroluminescence). The electrical signal 
is directly plugged into a portable display device, or a camera 
can be used to detect the luminescent output, and data is 
digitized. Gold electrodes functionalized with self-assembled 
thiol chemical groups have been used to detect ZIKV DNA 
in a device that measures impedance changes [73]. Electrode 
capacitance has also been used to detect DENV antigen-
antibody complexes [74]. 
IV. SMARTPHONE-BASED RAPID DIAGNOSTICS AND 
OTHER EMERGING TECHNOLOGIES 
During infectious disease pandemics, rapid testing delivers 
the means by which infected people are identified without 
overwhelming a clinical laboratory’s capacity for traditional 
benchtop testing. A key limitation with any rapid testing is 
interpretation of the result and its associated errors. There is 
therefore a need for real-time testing and in-field tracking 
that links cloud-based analysis and diagnosis messaging. 
Given the widespread global prevalence of smartphones, this 
would be considered as the current technology platform of 
choice. The smartphone itself acts as the diagnostic 
instrument whilst simultaneously transmitting and receiving 
data instantly to cloud-based databases and software [75]. 
This approach allows instant disease identification and 
notification locally, nationally or globally via mobile 
networks (Fig 5).  
 
A.  SMARTPHONE BASED NUCLEIC ACID TESTS 
Components for a fully integrated field device already exist 
for sample collection, nucleic acid extraction, amplification 
and signal processing. For example, extraction of nucleic 
acid (from respiratory samples) can be driven by low-power 
fans mounted onto the smartphone, providing centrifugal 
force-based extraction [76]. They can also be used in an in-
flight drone centrifuge and convective PCR run from a 
smartphone [77]. The nucleic acid test can be performed 
based on Rayleigh–Bernard natural convection for buoyancy-
driven thermal gradients of liquid heating [78-80]. Heating 
occurs from the bottom of the reaction, meaning a spatial 
temperature gradient established between the top (cool) and 
the bottom (hot) surfaces of the reactor, simulating a 
thermocycler. In other words, the movement of solutions by 
convection physically transports reagents between reaction 
zones. Renewable energy sources such as solar and body 
generated thermal heating can also be used [81, 82]. Self-
contained platforms have been reported for smartphone 
devices that perform both temperature tuneable and time-
resolved fluorescence measurements with continuous 
photographic and self-controlled timing of the detector [83, 
84]. There are also reports of rapid isothermal amplification 
for COVID-19 [85, 86]. In another example, a hot coffee 
mug is used to heat the RT-LAMP reaction for colorimetric 
detection of ZIKV RNA [87]. The device uses an innovative 
ball-based valve to enable the storage and delivery of 
reagents in a paper-based system within the mug for RNA 
enrichment and purification. In another design, water-
triggered exothermic materials offer a low-cost SmartCup 
energy efficient reaction [88]. Additionally, LAMP reactions 
are possible on microfluidic paper integrated with a 
smartphone fluorescent reader [89-92]. Moreover, 
multiplexing can achieve simultaneous reactions of different 
viruses [92-94], and indeed, a silicon microfluidic chip 
containing 10 parallel flow channels has been developed for 
multiplexed LAMP detection of bacterial and viral pathogens 
where a smartphone camera is used to capture the 
fluorescence readouts [92]. Finally, although analysis of the  

































FIGURE 4. Lateral flow-based detection devices. (A) General immunoassay technique using rapid diagnostic lateral flow assay (Image reproduced from [96] 
permission is not required). (B) A smartphone analyser for lateral flow tests reduces a large benchtop instrument into a portable hand carried device that automatically 
collects data and sends into the cloud. (Images C courtesy of AusSI Systems). 
 
NGS reads is generally performed using high-end server 
computers or cloud services requiring massive machine to 
machine data transfer through a broadband network, MinION 
is a compact portable devices that use similar technology 
allowing sequencing in the field [95]. Edge analysis greatly 
reduces bandwidth within an IoT network. Alternatively, 
bioinformatic analyses have been directly undertaken on the 
smartphone. This includes sequence alignments to detection 
of variants [97]. Near-real time sequence data analyses 
greatly enhance clinician and epidemiological data tracking 
[98] for deployment of optimal treatments. 
 
B.  SMARTPHONE-BASED ANTIBODY TESTS 
The digitization of the antibody colorimetry, albeit on a test 
strip or an ELISA plate, has long been part of measured 
outputs [99-102]. Several companies are aiming to develop 
single-use, disposable serological testing for SARS-CoV-2 
antibodies using smartphone devices [103]. Typically, the 
assay integrates smartphone camera imaging for rapid digital 
quantification of dot-based ELISA tests [104]. Early 
assessments suggest these rapid assays can match laboratory 
grade accuracy. Further, 3D-printing technology has been 
used to fabricate packaging and customized optics for 
multiplexed ELISA detection using smartphone cameras 
[105-107]. One drawback of smartphones as a diagnostic is 
that they do not have a consistent color correction, 
particularly for multiple color parameters, and color detection 
varies across models [108]. Nonetheless, individual 
smartphones can be calibrated and performances comparable 
with benchtop equipment. There are ample examples 
available with smartphone-based detection. Smartphone 
detection for avian influenza specific human serum 
antibodies has been achieved with a sensitivity of 96.5% and 
a specificity of 98.5% [109]. In another example, a 
smartphone camera images fluorescent labelled secondary 
antibodies in barcode-like patterns upon the recognition of 
the virus [93]. Here, the optics for excitation requires an 
additional external power source (typically, a monochromatic 
light source requiring a heavy power supply or rechargeable 
battery). This can limit POC portability. For some cases, 
however, it is possible that an excitation source can be 
powered by the smartphone in-built rechargeable battery or a 
USB connection to an external hard-wired power supply 
[110, 111]. Furthermore, electrochemical biosensors generate 
an electrical signal output or a luminescent emission [112-
116]. The output electrical signal can be directly plugged into 
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the smartphone via its micro-USB port and a luminescent 
output can be detected via the camera with subsequent 
digitizing of the output information. Several microcontroller 
platforms have delivered affordable electrochemical 
biosensors this way [112]. A geno-sensor device has been 
designed for the differential detection of ZIKV infection and 
its discrimination from other human flavivirus infections 
such as dengue virus [113]. In this example, the sensor 
captures signal probes and the PCR amplifies the target 
genetic material. Similarly, an electrochemical impedance 
sensor imprinted onto a traditional lateral flow strip has been 
reported for portable quantitative detection of ZIKV [114]. 
The impedimetric sensor uses a gold micro-electrode 
antibody-sensing chip – prepared via immobilization of 
ZIKV specific envelope protein antibody [114]. A portable 
platform has been developed to perform some of the more 
common electroanalytical techniques of chronoamperometry, 
differential pulse voltammetry and square wave voltammetry 
[115]. There are in fact a broad range of exciting new 
technologies being developed, in addition to smartphones, for 
rapid testing applications including SARS-COV-2 diagnosis. 
These are summarised below and in Table I. 
 
Most recently, an exciting new avenue in this space has 
been demonstrated. The detection of three chemical samples 
reference against a reference sample within a novel, rugged 
smartphone spectrometer is further evidence of what 
technology can achieve in simultaneous near real time 
measurements into the network [117, 118]. The potential to 
analyze multiple parameters and samples simultaneously in 
the field can only support and enhance the capability of a 
connected super diagnostic network. It illustrates the power 
and potential packed into the everyday consumer 
smartphone, a technology that is also expanding in other 
consumer products that will also help change the landscape. 
What also arises form this is the importance of pre-
processing edge computing within the smartphone to help 
reduce the bandwidth demanded by the network. 
 
C.  OPTICAL AND QUANTUM TECHNOLOGIES 
A number of photonic based methods are being applied to 
sensing and diagnostics. For example, a localized surface 
plasmon resonance (SPR) biosensor was reported using 2D 
gold nano-islands making up the plasmonic material and 
functionalized with cDNA probes as a sensor for SARS-
CoV-2 [119]. Nanoparticles within the surface plasmon 
excitation region have broad optical cross-sections coupled to 
non-radiative decay that produce highly localised heat upon 
optical absorption. This heat is adjusted to make it more 
difficult for imperfectly matched sequences, compared to the 
desired target, thereby reducing false-positive readings. In 
another SPR example, a metal-coated optical fiber generates 
a propagating plasmonic surface wave at the interface to 
measure changes in the refractive index of the environment 
being analyzed [120, 121]. Here, the refractive index changes 
with a virus antigen and antibody interaction. The level of 
sensitivity of the detection can be improved by using 3D-
printed novel fibers that increase surface interactions with the 
analytes [122, 123] as well as by using other fiber optic 
resonant components such as Bragg gratings [124]. Highly 
sensitive detection can also be achieved using biomedical 
waveguide interference between two optical modes [125]. 
The visible light interacts with analytes during propagation 
and the output interference is recorded using a photodetector 
array. The optical detection of SARS-CoV-2 coronavirus can 
be accelerated by combining the magnetic affinity of 
nanoparticles into the detection system [126]. This technique 
uses the virus RNA specific fluorescent probe that attaches to 
the viral RNA and emits light when excited by a laser at an 
appropriate wavelength. With the use of magnetic particles 
that adhere to the fluorescent molecules, a magnetic field can 
drive their movement through the solution leading to 
aggregation in the illumination area of the laser beam, 
helping to amplify measured signal strength. This technique 
can potentially detect ultra-low viral RNA concentrations 
[127].  
 
Optical imaging modalities (chest X-ray and CT scans) 
were initially used to diagnose the COVID-19 infections in 
patients in Wuhan hospitals [128]. The obvious issue here is 
that CT scans are nonspecific with respect to an infectious 
agent, although they can illustrate a certain pathophysiology 
and identify their anatomic location. In situations where 
clinicians are unavailable, such as in rural locations, or even 
in overly busy central hospitals, machine learning possibly 
with AI, might triage the incoming data to categorize patients 
relative to the limited available resources in pandemic 
settings [129]. The initial challenge is access sufficient 
realistic clinical data for algorithm training and to test and 
verify high accuracy. 
 
A significant limit to all testing is noise and, more 
specifically, shot noise limits that arise from the quantised 
particle nature of electronics and light in sources and 
detectors. When considering photon emissions from a source, 
the electronic transition is random in time, leading to 
fluctuations. In the classical domain, where many photons 
produced as an average, this is not detected except when the 
photon number becomes small. However, in the case of a 
diagnostic that needs to detect only a few photons (i.e. for 
single particle detection) then noise can limit detection 
reliability. Consequently, to get below the shot noise, control 
of emission of the photons is required and typically achieved 
using single photon emitters. Currently nitrogen vacancy 
centres in diamond are being used [130] and these have been 
applied to the detection of label-free DNA in microfluidic 
devices [65]. Small photodetectors optimised to reduce the 
shot noise can be designed. However, the detection of single 
photon emission itself requires correlation with a second 
single photon source [131]. The centres that make good  








Method Target Prospects Constraints 
Section A: Nucleic acid testing 
Smartphone 
RT-qPCR 
DENV DNA [132] 
Avian influ. DNA [79] 
Salmonella DNA [133] 
Human 18S ribosomal RNA 
[134] 
• Digital quantification makes multiplexed 
detection and identify co-infections 
• 3D-printable, auto sample injection and 
control  
• Smartphone processing and reporting, faster 
than clinical diagnosis (< 1 hr)  
• Thermal instability, power 
requirement and complex 
• Need interfaces of genome 
collection and extraction 




H1N1 influenza-A RNA [79] 
S. aureus DNA [77, 80] 
E. coli O157:H7 DNA [76] 
• Buoyancy driven natural convection 
• Less power and electronic control 
• On-board genome extraction using 
miniature fan/drone-based centrifuge 
• Open-loop temperature 
control 
• Lack of integrated sample 
preparation capability 
Solar thermal PCR Kaposi’s Sarcoma herpesvirus 
DNA [81] 
• Solar heating for PCR thermocycling 
• Low power (80 mW), fast response (<30 min) 
• Smartphone based fluorescence detection 
• Limited lifetime (phone 
battery) 
• Temperature adjustment 
needed for weather variation 
Smartphone 
LAMP 
ZIKV RNA [87] 
Herpes simplex virus DNA 
[88] 
SARS-CoV-2 RNA [86] 
Influenza-A H1N1, S. aureu 
[85] 
P. falciparum DNA [89] 
HIV RNA ; EHV1, EHV4 and 
EIV DNA [92]; ZIKV,  
ENV, CHIV RNA [90] 
• Fixed and relatively lower T requirement 
• Multiple primers increase specificity 
• Innovative designs of reaction chamber (e. 
g. SMART cup/mug) allow storage and 
sequential delivery of reagents, RNA 
enrichment and purification, exothermic 
chemical reaction 
• Fast POC test such as with smartphone set up 
(<40 mins) 
• Need an RNA extraction kit 
• Multiple primers and regent 
costs 
CRISPR crRNA of SARS-CoV-2 [41] 
 
• Ultra-sensitivity, specificity and accuracy 
• Colorimetric and fluorescence readouts 
• Capable of handling many samples at a time 
• No need of RNA separation and 
amplification 
• Limits uses at the patient’s 
end as it needs skilled 
operators 





HIV/syphilis IgM /or IgG 
[135] 
Influenza-A [104]  
Avian influenza H5N3, H7N1 
& H9N2 [109] 
CD4 test of HIV [136] 
Type-I pyrethroids in 
pesticides [137]   
 
• Low-power, ultra-portable with low-cost 
PAD 
• On-chip sample collection and purification 
with less hardware, user intervention and 
regent cost 
• Space and wavelength division multiplexed 
detections using smartphone optical readout  
• Rapid detection (10-30 mins) including 
asymptomatic carriers, site identification, 
geographical transmission and past infection 
• Comparable to clinical ELISA: sensitivity 
>90%) specificity >80%; accuracy >95% 
• Does not always show active 
infection  
• Variation of antibody levels: 
suffers sensitivity issues at 
early during an infection 
• Misleading results when 
cross-reactivity of 
antibodies specificity is 
evident 
• Many are yet to show 
effectiveness in COVID-19 




SARS-CoV-2 RNA [119] • Ultra-fast optical detection (6-10 minutes of 
viral RNA hybridization) 
• Specific and sensitive detection reduced 
false negative results 
• High precision optics 
alignment 
• Statistical hit-and-miss as 
interaction area are small 
which can reduce sensitivity 
FET-based nano-
biosensing 
SARS-CoV-1 RNA [138-140] 
Ebola VP40 matrix protein 
[141] 
 
• Low-cost, label-free detection 
• On-chip fabrication, wearable device 
• Novel functional material (graphene, 
silicene etc.) 
• Packaging and stability are 
challenging issues 
• Need electrical isolation 
Optical 
interferometry 
SARS-CoV-2  RNA/Antigen 
[142] 
• Ultra-fast optical detection (6-10 minutes of 
viral RNA hybridization) 
• Reduced false negative results 
• Demonstrated for SARS-CoV-2 detection 
• Packaging and stability are 
difficult 
 
AI-based imaging Patient lung image [128, 143] 
 
• Portable X-ray, CT, digital microscopy tools 
• Advanced computer vision, machine 
learning algorithms improves detection 
accuracy 
• Smart health system management and 
control 
• Insufficient data to train 
algorithm 
• Security, privacy issues 
• Low specificity of imaging 
tests. 
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single photon sources tend to have high quantum efficiencies 
which leads to higher intensity emission. 
 
D.  NANOMATERIALS AND NANOTECHNOLOGIES 
Nanomaterials, such as graphene or silicene, within 
nanodevices such as field-effect transistor-based transducers, 
can be used as bioreceptors for antigen or antibody, 
delivering high sensitivity [140]. These materials can act as 
the channel within a fluid environment and also as a liquid 
gate - where the channel material surface is attached with a 
sample under test [138, 139, 141]. Both a SARS-CoV spike 
glycoprotein-specific antibody, and the ACE2 receptor 
protein have been crosslinked to graphene [138, 139, 141].  
When integrated as channels within isoporous membranes 
this approach achieves high affinity detection [144]. 
 
Nanomaterial porosity offers a filtration function, 
particularly when integrated in novel formats, and self-
assembly fabrication reduces cost, producing bulk amounts 
of high uniformity [130, 145]. Such structures have been 
identified as suitable in optimising hydrogen generation 
[146]. These nanomaterial wires promise a new generation of 
diffusive strips that could outperform current paper-based 
approaches that rely on randomized pore sizes that limit the 
resolution of lateral flow tests. This is a rapidly developing 
area and future innovations are certain to significantly disrupt 
POC diagnostic test capabilities. 
 
E.  WEARABLE SENSORS AND SMART FABRICS 
Current technologies for wearable sensors integrate 
nanomaterials for a variety of functional readouts with 
applications ranging from sports and endurance monitoring 
to health readouts. For example, thermal sensing fabrics can 
be produced by incorporating conductive polymers, 
graphene, nickel, silver and copper metal nanoparticles and 
nanowires (for recent reviews see [147] and [148]). 
Currently, multi-modal biosensors are expected, and they 
typically include temperature, pressure, and biomaterials 
for detection and monitoring excretions and metabolites. 
These wearable sensors can be embedded onto human skin 
or prepared within worn human devices, even fabrics or 
items such as mouth guards. They typically monitor heart 
rate, blood pressure and/or metabolites. Wearable devises 
monitoring body temperature (symptoms of fever) [149] 
and blood oxygen levels are particularly relevant to 
COVID-19 where hypoxia is a typical presentation of 
SARS-CoV-2 infected symptomatic patients with 
pneumonia. Additionally, automatic alarms can be built-in. 
These can, for example, be used to alert when temperature 
thresholds are reached. 
 
Smart textiles design and treatments with anti-viral agents 
can create an invisible coating that inhibits viral 
sustainability. For example, it was mentioned earlier that 
known anti-virals can be inserted into face masks. Coatings 
that can repel liquids and potentially prevent viruses from 
adhering to the surface have also been demonstrated [150]. It 
has long been known that silver-based technologies can 
destroy enveloped viruses including coronaviruses by 
99.99% [151] and, using this, a “disinfectant velvet” has been 
developed that is capable of photocatalysis when exposed to 
UV light [14]. Silver ions in various formats are impregnated 
into material for face masks for their anti-viral properties. 
These technologies are rapidly expanding, and although 
clearly exciting, a degree of caution is required because the 
degree of accuracy of these detection fabrics, and the limits 
of sensitivity are yet to be properly evaluated. Yet a highly 
infectious person might one day be both contained, detected 
and identified using masks comprised of smart fabrics. 
V. NETWORK DIAGNOSTICS OF DISEASES AND REAL-
TIME BIOINFORMATICS CAPABILITIES 
Smart diagnostic tools include smartphones, smart-watches, 
smart cloths, wearable devices and smart body implants with 
bio-receptor elements and smart functional materials. These 
tools can allow large-scale collection of patients’ information 
in real-time. This allows aggregation of “big data” compiled 
and processed in real time via global IoT networks. Such an 
advance will mark a new generation of disease “network 
diagnostics” where monitoring is powered by “swarm” 
artificial intelligence (AI) arising from the use of millions of 
field devices taking advantage of federated learning where an 
algorithm is trained across multiple decentralized 
smartphones or other devices operating at the network edge 
and servers where sample data is stored. In effect, the 
diagnosis happens at the patients’ ends. The information is 
coordinated and distributed for use directly, nationally or 
even internationally. Communication can be two-way with 
interconnected sensors being capable of communicating to 
each other, as well as centrally, using multi-layered 
architecture communication networks for both transmission 
and reception.  
 
The perception layer is the physical layer, where sensors 
collects information at the point-of-interest (i.e. the patient at 
their location) and processes the information. Smartphone 
camera sensors are customarily used as colorimetric and 
fluorescence detection in many PCR, LAMP and various 
rapid tests devices for virus nucleic acid or antibody/antigen 
detection (discussed earlier summarized in Table I). Multiple 
diagnostics can be undertaken at patients’ sites where the 
location information for mapping and tracking can be 
collected through GPS and other positioning sensing 
approaches. For example, heat detection of people with fever, 
individually or within small or large groups can be mapped. 
It can be individual-based or crowd-based sensing connected 
made possible via a dedicated sensor network. Distributed 
sensors can be positioned to monitor within surrounding 
infrastructure.  
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The network layer involves automated data collection. 
Conventionally, this is achieved through edge sensors that 
transmit data to wireless base stations and from there via 
optical fiber into the cloud where the applications layer 
     
FIGURE 5. Transmission networks underpin the internet and cloud-based diagnostics and informatics capabilities. Diagnostics at the perception layer feeds 
into the cloud via the edge using various transmission capabilities such as wireless and optical fibers. Alternatives exist for how data can be transferred. The results are 
collected at a central server from detection sites by the sensor devices which are used to analyze sequence, predict virus types using AI and develop a suitable vaccine 
which can be prescribed to the affected sites. 
 
resides. “Smart” platforms largely deployed in the perception 
layer can use a wide range of communications such as 
Bluetooth, LoRaWAN, Li-Fi, local 5G, Wi-Fi, GSM and 
satellite including localization (GPS). Whilst the smartphone 
is typically transmitting in RF or mm domain (from 3G to 
5G, and by ~2030 6G, depending on location), the sensor 
itself may be decoupled and transmit data to the smartphone 
and other mobile base units (MBU) via various protocols. 
Examples currently used in the medical space include 
acoustic and Bluetooth supported by Arduino, Raspberry Pi, 
Beaglebone Black and others. All these methods used in any 
arbitrary number of devices can be integrated together via the 
IoT, and when coupled with federated learning, be integrated 
directly together for simultaneous global mapping and more. 
 
The application layer includes application specific 
software and database analysis. Data from the previous levels 
are stored, aggregated, filtered, processed and analyzed. 
Once integrated, all the tools of analysis, from data collection 
to machine learning (ML) and AI derived decisions that 
expedite turnarounds, can be brought to bear both at the edge 
and across the cloud that describe much of the IoT 
infrastructure. For example, simply linking automation and 
rapid diagnostics permits comparisons to pre-existing 
reference data including virus nucleic acid genome 
sequences, instantaneously via cloud connectivity. This 
increases the value of the data by reducing translation times 
and reducing the potential for data errors. These 
communication networks allow for direct linkages to be 
made in all directions, simultaneously. They offer a new  
 
paradigm for immediate disease tracking and control. Global 
ubiquity can theoretically provide equal global accessibility, 
an important social aspect that may prove more challenging 
to resolve than the technology.  
 
Real-time communication permits quick translation of 
information that can deliver optimal treatment – basically, 
real time tracking compared to that currently used for 
COVID-19. For example, specific diagnosis of a distinct 
variant irrespective of the location of any infected patient is 
feasible as illustrated in Fig 5. The general concept has been 
virtually tested in a simulated respiratory virus epidemic 
already with the British Broadcasting Corporation 
documentary “Pandemic” that describes a situation where a 
smartphone application was employed in a hypothetical 2018 
new influenza epidemic as part of a “citizen science” 
experiment. 28,965 people in the UK voluntarily provided 
their contact and movement data from their smartphone 
(collected by GPS). This was transmitted to a central server 
and applied in a time-series analysis to determine the 
incidence cases and the origins of the infection [98]. Two 
different scenarios were studied: (1) the start of the outbreak 
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within a local town (Haslemere in Surrey; within-patch), and 
(2) the spread of the pandemic through the UK (between-
patches). The analysis used a discrete-time SIR (susceptible 
people – infectious – recovered) model to determine the 
output parameters. It considered the user profile, their 
movement, encounter times, relative transmission co-
efficient and reproduction ratio [152]. Although this analysis 
did not explicitly include the mortality rate, it did 
successfully demonstrate how the extra control measures can 
considerably slow down an infectious outbreak to reduce its 
impact [152]. Improving on this, individual sensors can be 
embedded within this network, providing Health Officials 
with real-time diagnostic tracking information and location 
mapping. That would enable near-instant targeted response 
containment, control and treatment measures. 
 
As with all informatics the utility of the data is highly 
dependent on the quality of the direct measurement. Machine 
learning or AI can be an invaluable tool for accelerating and 
automating analysis with increasing accuracy – whether it be 
to filter out the negatives or to positively identify different 
type or stages of infection cases [129, 153]. Quickly 
screening and removing negative test results builds resilience 
to testing errors. An intelligent global network can facilitate 
the reduction of individual testing, otherwise needed, by 
utilizing full statistical analysis to identify and isolate 
significant errors across the measured ecosystem as a whole. 
Already, a neural network framework through deep learning 
has shown a COVID-19 prediction accuracy of 82% using 
smartphone sensor measurements [154]. This will likely 
increase once these approaches are trialled more broadly and 
frequently. Whilst bioinformatics is still in its infancy, the 
spread of smartphone detection instrumentation and edge 
processing, coupled with swarm technologies, means 
implementation of mass data analytics in real-time is near 
and highly likely to be the employed early in future global 
pandemics. The quality of guaranteed data transmission, or 
connectivity, is another current concern since not all 
countries have extensive or modern network infrastructure. 
This problem is familiar to those in IoT where regional 
application of technology in rural settings even within 
developed countries have unreliable connectivity. 
Nonetheless, demonstrations of current capabilities exist: US 
FDA approved heart ECG monitors that function well, 
including across ocean distances over time, are commercially 
available [155].  
 
At present, however, the need to include secure and 
equitable data transmission and an analysis that is 
accountable to national and globally agreed standards 
cognisant of accepted ethical standards are political and 
social challenges that need addressing. Exactly “what” and 
“how” data is to be shared - across state or country borders – 
and the issue of ownership of the electronic data, must be 
addressed imminently. Indeed the WHO has recommended 
that a global diagnostics internet be centralized and 
administered by a universally accepted authority [156]. Thus, 
the global COVID-19 pandemic has already begun to 
accelerate these types of technology uses – whether the 
political and social will is there to connect the world fairly 
remains to be seen. 
 
VI. CONCLUSION 
This paper presents a cross-disciplinary review on pandemic 
respiratory virus detection, particularly SARS-CoV-2. It 
focusses on the transmission mechanisms, detection methods, 
smart POC testing and connected network-based informatics. 
We discuss the nature of surface water, how it exists, and 
interacts as aerosols and droplets, in a manner that permits 
virus infection transmission, an issue that has largely not 
been considered previously but which offers practical 
solutions for treatment and detection. We review the 
laboratory and POC possibilities for virus detection. Finally, 
the review embraces a range of new and emerging smart 
diagnostics and sensor tools, powered by lab-in-a-phone type 
technologies, and internet connectivity, for real-time 
detection and monitoring with global-cloud data 
accumulation and utilization by Health Officials. This real 
time detection need not be confined to one target only, with 
recent advances demonstrating multiple analyte 
measurements performed simultaneously that can be 
integrated into this network. Given the potential of this 
technology across sectors, a challenge will eventually arise 
from bandwidth demands and a need to practically balance 
edge and cloud computing, storage and analysis to optimise 
connectivity differences across and within regions. These 
ongoing developments are unlikely to fully replace gold-
standard laboratory PCR-based nucleic acid testing because it 
too will be integrated into the network serving as benchmark 
reference points for all analysis. A key advantage of these 
networks will be near real time diagnostics and potential 
resilience in mass diagnostics with lower quality assays and 
other tests. They will also reduce error from current, 
overwhelmingly manual, sample collection. Therefore, the 
test of choice in the future will be more about those tests that 
can be integrated in volume, into a hardware driven real-time 
informatics network diagnostic, where increasingly edge 
computation, as well as cloud analytics relying on collective 
data. As is abundantly evident with COVID-19, pandemics 
are global, spread through numerous vectors and 
environmental factors. Therefore, a global “super diagnostic” 
that has not yet been available, may emerge - a global 
network “super diagnostic” instrument capable of identifying 
disease and/or monitoring infected individuals, so as to 




          M. A. Hossain et al: Rapid Testing & Bioinformatic Analysis of SARS-CoV-2 and Human Respiratory Viruses in Pandemics 
16 
 
[1] K. G. Andersen, A. Rambaut, W. I. Lipkin, E. C. Holmes, and R. F. 
Garry, "The proximal origin of SARS-CoV-2," Nature Medicine, vol. 
26, no. 4, pp. 450-452, Apr. 2020. 
[2] WHO Coronavirus Disease (COVID-19) Dashboard [Online]. 
Available: https://covid19.who.int/ 
[3] A. Sette and S. Crotty, "Pre-existing immunity to SARS-CoV-2: the 
knowns and unknowns," Nature Reviews Immunology, vol. 20, no. 8, 
pp. 457-458, Aug. 2020. 
[4] Y. Tang, J. Liu, D. Zhang, Z. Xu, J. Ji, and C. Wen, "Cytokine Storm 
in COVID-19: The Current Evidence and Treatment Strategies," 
Front Immunol, Review vol. 11, no. 1708, p. 1708, Jul. 2020. 
[5] L. Verdoni et al., "An outbreak of severe Kawasaki-like disease at 
the Italian epicentre of the SARS-CoV-2 epidemic: an observational 
cohort study," Lancet, vol. 395, no. 10239, pp. 1771-1778, Jun. 2020. 
[6] J. B. Dowd et al., "Demographic science aids in understanding the 
spread and fatality rates of COVID-19," Proceedings of the National 
Academy of Sciences, vol. 117, no. 18, p. 9696, May 2020. 
[7] K. Kupferschmidt and M. Wadman, "Delta variant triggers new 
phase in the pandemic," Science, vol. 372, no. 6549, p. 1375, 2021. 
[8] J. W. Tang, O. T. R. Toovey, K. N. Harvey, and D. D. S. Hui, 
"Introduction of the South African SARS-CoV-2 variant 501Y.V2 
into the UK," The Journal of infection, pp. S0163-4453(21)00030-X, 
Jan. 2021. 
[9] D. Cyranoski, "Mystery deepens over animal source of coronavirus," 
Nature, vol. 579, no. 7797, pp. 18-19, Mar. 2020. 
[10] M. Fang, W. Hu, and B. Liu, "Characterization of bat coronaviruses: 
a latent global threat," (in eng), Journal of veterinary science, vol. 
22, no. 5, pp. e72-e72, 2021. 
[11] A. Hassanin, V. T. Tu, M. Curaudeau, and G. Csorba, "Inferring the 
ecological niche of bat viruses closely related to SARS-CoV-2 using 
phylogeographic analyses of Rhinolophus species," Scientific 
Reports, vol. 11, no. 1, p. 14276, 2021 Jul 2021. 
[12] L. J. Carter et al., "Assay Techniques and Test Development for 
COVID-19 Diagnosis," ACS Central Science, vol. 6, no. 5, pp. 591-
605, May 2020. 
[13] F. Cui and H. S. Zhou, "Diagnostic methods and potential portable 
biosensors for coronavirus disease 2019," Biosens Bioelectron, vol. 
165, p. 112349, Oct. 2020. 
[14] M. Raeiszadeh and B. Adeli, "A Critical Review on Ultraviolet 
Disinfection Systems against COVID-19 Outbreak: Applicability, 
Validation, and Safety Considerations," ACS Photonics, vol. 7, no. 
11, pp. 2941-2951, Nov. 2020. 
[15] B. Udugama et al., "Diagnosing COVID-19: The Disease and Tools 
for Detection," ACS Nano, vol. 14, no. 4, pp. 3822-3835, Apr. 2020. 
[16] V. Chamola, V. Hassija, V. Gupta, and M. Guizani, "A 
Comprehensive Review of the COVID-19 Pandemic and the Role of 
IoT, Drones, AI, Blockchain, and 5G in Managing its Impact," IEEE 
Access, vol. 8, pp. 90225-90265, 2020. 
[17] C. Eastin and T. Eastin, "Clinical Characteristics of Coronavirus 
Disease 2019 in China: Guan W, Ni Z, Hu Y, et al. N Engl J Med. 
2020 Feb 28 [Online ahead of print] DOI: 
10.1056/NEJMoa2002032," (in eng), The Journal of Emergency 
Medicine, vol. 58, no. 4, pp. 711-712, 2020. 
[18] Q. Li et al., "Early Transmission Dynamics in Wuhan, China, of 
Novel Coronavirus–Infected Pneumonia," New England Journal of 
Medicine, vol. 382, no. 13, pp. 1199-1207, 2020/03/26 2020. 
[19] L. M. Kucirka, S. A. Lauer, O. Laeyendecker, D. Boon, and J. 
Lessler, "Variation in False-Negative Rate of Reverse Transcriptase 
Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time 
Since Exposure," Annals of Internal Medicine, vol. 173, no. 4, pp. 
262-267, Aug. 2020. 
[20] S. Riddell, S. Goldie, A. Hill, D. Eagles, and T. W. Drew, "The 
effect of temperature on persistence of SARS-CoV-2 on common 
surfaces," Virology Journal, vol. 17, no. 1, p. 145, Oct. 2020. 
[21] D. Lewis, "Mounting evidence suggests coronavirus is airborne - but 
health advice has not caught up," (in eng), Nature, vol. 583, no. 
7817, pp. 510-513, Jul 2020. 
[22] J. Canning, "Water photonics, non-linearity, and anomalously large 
electro-optic coefficients in poled silica fibers," MRS 
Communications, vol. 8, no. 1, pp. 29-34, Feb. 2018. 
[23] H. EUROPA, "COVID-19 nasal spray effective against variants," ed, 
02.07.2021. 
[24] C. L. Li, L. G. Martini, J. L. Ford, and M. Roberts, "The use of 
hypromellose in oral drug delivery," Journal of Pharmacy and 
Pharmacology, https://doi.org/10.1211/0022357055957 vol. 57, no. 
5, pp. 533-546, 2005/05/01 2005. 
[25] K. Shmuel, M. Dalia, L. Tair, and N. Yaakov, "Low pH 
Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-
2 infection rate post mass-gathering event at a highly endemic 
community: an observational prospective open label user survey," 
Expert Review of Anti-infective Therapy, pp. 1-6, 2021. 
[26] H. Huang, H. Park, Y. Liu, and J. Huang, "On-Mask Chemical 
Modulation of Respiratory Droplets," Matter, vol. 3, no. 5, pp. 1791-
1810, Nov. 2020. 
[27] J. Canning, "Optical hoovering on plasmonic rinks," MRS 
Communications, vol. 9, no. 3, pp. 1072-1078, Jul. 2019. 
[28] M. Triplett, "Evidence that higher temperatures are associated with 
lower incidence of COVID-19 in pandemic state, cumulative cases 
reported up to March 27, 2020," medRxiv, p. 2020.04.02.20051524, 
2020. 
[29] F. Xiao, M. Tang, X. Zheng, Y. Liu, X. Li, and H. Shan, "Evidence 
for Gastrointestinal Infection of SARS-CoV-2," Gastroenterology, 
vol. 158, no. 6, pp. 1831-1833 e3, May 2020. 
[30] K. R. McKinney, Y. Y. Gong, and T. G. Lewis, "Environmental 
transmission of SARS at Amoy Gardens," J Environ Health, vol. 68, 
no. 9, pp. 26-30; quiz 51-2, May 2006. 
[31] Status of environmental surveillance for SARS-CoV-2 virus, 
Scientific Brief [Online]. Available: https://www.who.int/news-
room/commentaries/detail/status-of-environmental-surveillance-for-
sars-cov-2-virus 
[32] W. Wang et al., "Detection of SARS-CoV-2 in Different Types of 
Clinical Specimens," JAMA, vol. 323, no. 18, pp. 1843-1844, Mar. 
2020. 
[33] I. V. Kutyavin et al., "3'-minor groove binder-DNA probes increase 
sequence specificity at PCR extension temperatures," Nucleic acids 
research, vol. 28, no. 2, pp. 655-661, Jan. 2000. 
[34] H. D. VanGuilder, K. E. Vrana, and W. M. Freeman, "Twenty-five 
years of quantitative PCR for gene expression analysis," 
Biotechniques, vol. 44, no. 5, pp. 619-26, Apr. 2008. 
[35] E. L. A. Howson et al., "Defining the relative performance of 
isothermal assays that can be used for rapid and sensitive detection of 
foot-and-mouth disease virus," Journal of virological methods, vol. 
249, pp. 102-110, Aug. 2017. 
[36] L. E. Lamb, S. N. Bartolone, E. Ward, and M. B. Chancellor, "Rapid 
detection of novel coronavirus/Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-
mediated isothermal amplification," (in eng), PloS one, vol. 15, no. 6, 
pp. e0234682-e0234682, Jun. 2020. 
[37] L. Mautner et al., "Rapid point-of-care detection of SARS-CoV-2 
using reverse transcription loop-mediated isothermal amplification 
(RT-LAMP)," Virology Journal, vol. 17, no. 1, p. 160, Oct. 2020. 
[38] L. Yu et al., "Rapid Detection of COVID-19 Coronavirus Using a 
Reverse Transcriptional Loop-Mediated Isothermal Amplification 
(RT-LAMP) Diagnostic Platform," Clin Chem, vol. 66, no. 7, pp. 
975-977, Jul. 2020. 
[39] F. Hu et al., "Smartphone-Based Droplet Digital LAMP Device with 
Rapid Nucleic Acid Isolation for Highly Sensitive Point-of-Care 
Detection," Anal Chem, vol. 92, no. 2, pp. 2258-2265, Jan. 2020. 
[40] J. S. Gootenberg et al., "Nucleic acid detection with CRISPR-
Cas13a/C2c2," Science, vol. 356, no. 6336, pp. 438-442, Apr. 2017. 
[41] J. P. Broughton et al., "CRISPR–Cas12-based detection of SARS-
CoV-2," Nature Biotechnology, vol. 38, no. 7, pp. 870-874, Jul. 
2020. 
[42] J. Joung et al., "Point-of-care testing for COVID-19 using 
SHERLOCK diagnostics," medRxiv : the preprint server for health 
sciences, p. 2020.05.04.20091231, May 8, 2020. 
[43] M. J. Kellner, J. G. Koob, J. S. Gootenberg, O. O. Abudayyeh, and F. 
Zhang, "SHERLOCK: nucleic acid detection with CRISPR 
nucleases," Nat Protoc, vol. 14, no. 10, pp. 2986-3012, Oct. 2019. 
[44] P. Fozouni et al., "Amplification-free detection of SARS-CoV-2 with 
CRISPR-Cas13a and mobile phone microscopy," Cell, vol. 184, no. 
2, pp. 323-333.e9, Jan. 2021. 
          M. A. Hossain et al: Rapid Testing & Bioinformatic Analysis of SARS-CoV-2 and Human Respiratory Viruses in Pandemics 
17 
 
[45] P. Zhou et al., "A pneumonia outbreak associated with a new 
coronavirus of probable bat origin," Nature, vol. 579, no. 7798, pp. 
270-273, Mar. 2020. 
[46] L. Chen et al., "RNA based mNGS approach identifies a novel 
human coronavirus from two individual pneumonia cases in 2019 
Wuhan outbreak," Emerging Microbes & Infections, vol. 9, no. 1, pp. 
313-319, Jan. 2020. 
[47] V. Hul et al., "A novel SARS-CoV-2 related coronavirus in bats 
from Cambodia," bioRxiv, p. 2021.01.26.428212, Jan. 26, 2021. 
[48] H. Zhou et al., "A Novel Bat Coronavirus Closely Related to SARS-
CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the 
Spike Protein," Current Biology, vol. 30, no. 19, p. 3896, Jun. 2020. 
[49] T. T.-Y. Lam et al., "Identifying SARS-CoV-2-related coronaviruses 
in Malayan pangolins," Nature, vol. 583, no. 7815, pp. 282-285, Jul. 
2020. 
[50] GenBank Overview [Online]. Available: 
https://www.ncbi.nlm.nih.gov/genbank/ 
[51] GISAID [Online]. Available: https://www.gisaid.org/ 
[52] Pango lineages [Online]. Available: https://cov-
lineages.org/pango_lineages.html 
[53] A. Rambaut. Preliminary genomic characterisation of an emergent 
SARS-CoV-2 lineage in the UK defined by a novel set of spike 
mutations [Online]. Available: https://virological.org/ 
[54] J. Trifinopoulos, L.-T. Nguyen, A. von Haeseler, and B. Q. Minh, 
"W-IQ-TREE: a fast online phylogenetic tool for maximum 
likelihood analysis," Nucleic Acids Research, vol. 44, no. W1, pp. 
W232-W235, Jul. 2016. 
[55] QGIS, A Free and Open Source Geographic Information System 
[Online]. Available: https://qgis.org/en/site/ 
[56] Insightful Science [Online]. Available: https://www.snapgene.com/ 
[57] G. Marano et al., "Convalescent plasma: new evidence for an old 
therapeutic tool?," Blood Transfus, vol. 14, no. 2, pp. 152-7, Mar. 
2016. 
[58] D. Focosi, A. O. Anderson, J. W. Tang, and M. Tuccori, 
"Convalescent Plasma Therapy for COVID-19: State of the Art," 
Clinical Microbiology Reviews, vol. 33, no. 4, pp. e00072-20, Aug. 
2020. 
[59] R. Li et al., "Substantial undocumented infection facilitates the rapid 
dissemination of novel coronavirus (SARS-CoV-2)," Science, vol. 
368, no. 6490, p. 489, May 2020. 
[60] N. Iwanaga et al., "Novel ACE2-IgG1 fusions with improved activity 
against SARS-CoV2," bioRxiv : the preprint server for biology, p. 
2020.06.15.152157, Jun. 15, 2020. 
[61] S. Miersch et al., "Synthetic Antibodies neutralize SARS-CoV-2 
infection of mammalian cells," p. 2020.06.05.137349, 2020. 
[62] E. B. Bahadır and M. K. Sezgintürk, "Lateral flow assays: Principles, 
designs and labels," TrAC Trends in Analytical Chemistry, vol. 82, 
pp. 286-306, Sep. 2016. 
[63] In Vitro Diagnostics EUAs, Coronavirus Disease 2019 (COVID-19) 




[64] C. F. Schuler et al., "Accurate point-of-care serology tests for 
COVID-19," (in eng), PloS one, vol. 16, no. 3, pp. e0248729-
e0248729, 2021. 
[65] W. Leber, O. Lammel, A. Siebenhofer, M. Redlberger-Fritz, J. 
Panovska-Griffiths, and T. Czypionka, "Comparing the diagnostic 
accuracy of point-of-care lateral flow antigen testing for SARS-CoV-
2 with RT-PCR in primary care (REAP-2)," EClinicalMedicine, p. 
101011, 2021/07/13/ 2021. 
[66] S. K. Vashist, E. M. Schneider, and J. H. Luong, "Commercial 
Smartphone-Based Devices and Smart Applications for Personalized 
Healthcare Monitoring and Management," Diagnostics (Basel), vol. 
4, no. 3, pp. 104-28, Aug. 2014. 
[67] J. L. D. Nelis, A. S. Tsagkaris, M. J. Dillon, J. Hajslova, and C. T. 
Elliott, "Smartphone-based optical assays in the food safety field," 
TrAC Trends in Analytical Chemistry, vol. 129, p. 115934, Aug. 
2020. 
[68] K. H. Foysal, S. E. Seo, M. J. Kim, O. S. Kwon, and J. W. Chong, 
"Analyte Quantity Detection from Lateral Flow Assay Using a 
Smartphone," Sensors (Basel, Switzerland), vol. 19, no. 21, p. 4812, 
Nov. 2019. 
[69] P.-H. Lu, Y.-D. Ma, C.-Y. Fu, and G.-B. Lee, "A structure-free 
digital microfluidic platform for detection of influenza a virus by 
using magnetic beads and electromagnetic forces," Lab on a Chip, 
10.1039/C9LC01126A vol. 20, no. 4, pp. 789-797, Feb. 2020. 
[70] Y. Xia, J. Si, and Z. Li, "Fabrication techniques for microfluidic 
paper-based analytical devices and their applications for biological 
testing: A review," Biosensors and Bioelectronics, vol. 77, pp. 774-
789, Mar. 2016. 
[71] J. T. Heggestad et al., "Multiplexed, quantitative serological profiling 
of COVID-19 from blood by a point-of-care test," Science Advances, 
vol. 7, no. 26, p. eabg4901, 2021. 
[72] B. S. Batule, Y. Seok, and M.-G. Kim, "Paper-based nucleic acid 
testing system for simple and early diagnosis of mosquito-borne 
RNA viruses from human serum," Biosensors and Bioelectronics, 
vol. 151, p. 111998, Mar. 2020. 
[73] H. A. M. Faria and V. Zucolotto, "Label-free electrochemical DNA 
biosensor for zika virus identification," Biosensors and 
Bioelectronics, vol. 131, pp. 149-155, Apr. 2019. 
[74] J. Cecchetto, A. Santos, A. Mondini, E. M. Cilli, and P. R. Bueno, 
"Serological point-of-care and label-free capacitive diagnosis of 
dengue virus infection," Biosensors and Bioelectronics, vol. 151, p. 
111972, Mar. 2020. 
[75] P. C. Biswas, S. Rani, M. A. Hossain, M. R. Islam, and J. Canning, 
"Recent Developments in Smartphone Spectrometer Sample 
Analysis," IEEE Journal of Selected Topics in Quantum Electronics, 
vol. 27, no. 6, pp. 1-12, 2021. 
[76] Y. M. Park, C. H. Kim, S. J. Lee, and M.-K. Lee, "Multifunctional 
hand-held sensor using electronic components embedded in 
smartphones for quick PCR screening," Biosensors and 
Bioelectronics, vol. 141, p. 111415, Sep. 2019. 
[77] A. Priye et al., "Lab-on-a-Drone: Toward Pinpoint Deployment of 
Smartphone-Enabled Nucleic Acid-Based Diagnostics for Mobile 
Health Care," Analytical Chemistry, vol. 88, no. 9, pp. 4651-4660, 
May 2016. 
[78] A. Priye and V. Ugaz, DNA-to-go: A portable smartphone-enabled 
PCR assay platform. 2014. 
[79] X. Qiu et al., "A smartphone-based point-of-care diagnosis of H1N1 
with microfluidic convection PCR," Microsystem Technologies, vol. 
23, no. 7, pp. 2951-2956, Jul. 2017. 
[80] V. K. Rajendran, P. Bakthavathsalam, P. L. Bergquist, and A. Sunna, 
"Smartphone detection of antibiotic resistance using convective PCR 
and a lateral flow assay," Sensors and Actuators B: Chemical, vol. 
298, p. 126849, Nov. 2019. 
[81] L. Jiang, M. Mancuso, Z. Lu, G. Akar, E. Cesarman, and D. 
Erickson, "Solar thermal polymerase chain reaction for smartphone-
assisted molecular diagnostics," Scientific Reports, vol. 4, no. 1, p. 
4137, Feb. 2014. 
[82] M. Kong et al., "A wearable microfluidic device for rapid detection 
of HIV-1 DNA using recombinase polymerase amplification," 
Talanta, vol. 205, p. 120155, Dec. 2019. 
[83] M. A. Hossain et al., "Time-resolved and temperature tuneable 
measurements of fluorescent intensity using a smartphone 
fluorimeter," Analyst, 10.1039/C7AN00535K vol. 142, no. 11, pp. 
1953-1961, Jun. 2017. 
[84] Y. Jiang, B. Li, and W. Wu, "Application of automatic feedback 
photographing by portable smartphone in PCR," Sensors and 
Actuators B: Chemical, vol. 298, p. 126782, Nov. 2019. 
[85] Y.-D. Ma et al., "A sample-to-answer, portable platform for rapid 
detection of pathogens with a smartphone interface," Lab on a Chip, 
10.1039/C9LC00797K vol. 19, no. 22, pp. 3804-3814, Nov. 2019. 
[86] M. El-Tholoth, H. H. Bau, and J. Song, "A Single and Two-Stage, 
Closed-Tube, Molecular Test for the 2019 Novel Coronavirus 
(COVID-19) at Home, Clinic, and Points of Entry," ChemRxiv : the 
preprint server for chemistry, p. 10.26434/chemrxiv.11860137.v1, 
Feb 19, 2020. 
[87] X. Jiang, J. C. Loeb, C. Manzanas, J. A. Lednicky, and Z. H. Fan, 
"Valve-Enabled Sample Preparation and RNA Amplification in a 
Coffee Mug for Zika Virus Detection," Angew Chem Int Ed Engl, 
vol. 57, no. 52, pp. 17211-17214, Dec. 2018. 
          M. A. Hossain et al: Rapid Testing & Bioinformatic Analysis of SARS-CoV-2 and Human Respiratory Viruses in Pandemics 
18 
 
[88] S.-C. Liao et al., "Smart cup: A minimally-instrumented, 
smartphone-based point-of-care molecular diagnostic device," 
Sensors and Actuators B: Chemical, vol. 229, pp. 232-238, Jun. 
2016. 
[89] J. Reboud et al., "Paper-based microfluidics for DNA diagnostics of 
malaria in low resource underserved rural communities," 
Proceedings of the National Academy of Sciences, vol. 116, no. 11, 
p. 4834, Mar. 2019. 
[90] A. Ganguli et al., "Hands-free smartphone-based diagnostics for 
simultaneous detection of Zika, Chikungunya, and Dengue at point-
of-care," Biomed Microdevices, vol. 19, no. 4, p. 73, Aug. 2017. 
[91] W. Chen et al., "Mobile Platform for Multiplexed Detection and 
Differentiation of Disease-Specific Nucleic Acid Sequences, Using 
Microfluidic Loop-Mediated Isothermal Amplification and 
Smartphone Detection," Anal Chem, vol. 89, no. 21, pp. 11219-
11226, Nov. 2017. 
[92] F. Sun et al., "Smartphone-based multiplex 30-minute nucleic acid 
test of live virus from nasal swab extract," Lab on a Chip, 
10.1039/D0LC00304B vol. 20, no. 9, pp. 1621-1627, Apr. 2020. 
[93] J. Kim, M. J. Biondi, J. J. Feld, and W. C. W. Chan, "Clinical 
Validation of Quantum Dot Barcode Diagnostic Technology," ACS 
Nano, vol. 10, no. 4, pp. 4742-4753, Apr. 2016. 
[94] Y. Seok et al., "A Paper-Based Device for Performing Loop-
Mediated Isothermal Amplification with Real-Time Simultaneous 
Detection of Multiple DNA Targets," Theranostics, vol. 7, no. 8, pp. 
2220-2230, Jul. 2017. 
[95] H. Samarakoon et al., "Genopo: a nanopore sequencing analysis 
toolkit for portable Android devices," Communications Biology, vol. 
3, no. 1, p. 538, Sep. 2020. 
[96] Z. Li et al., "Development and clinical application of a rapid IgM-
IgG combined antibody test for SARS-CoV-2 infection diagnosis," 
Journal of Medical Virology, https://doi.org/10.1002/jmv.25727 vol. 
92, no. 9, pp. 1518-1524, 2020/09/01 2020. 
[97] A. Palatnick, B. Zhou, E. Ghedin, and M. C. Schatz, "iGenomics: 
Comprehensive DNA sequence analysis on your Smartphone," 
GigaScience, vol. 9, no. 12, Dec. 2020. 
[98] P. Klepac, S. Kissler, and J. Gog, "Contagion! The BBC Four 
Pandemic – The model behind the documentary," Epidemics, vol. 24, 
pp. 49-59, Sep. 2018. 
[99] M. A. Kabir, H. Zilouchian, M. Sher, and W. Asghar, "Development 
of a Flow-Free Automated Colorimetric Detection Assay Integrated 
with Smartphone for Zika NS1," Diagnostics (Basel, Switzerland), 
vol. 10, no. 1, p. 42, Jan. 2020. 
[100] A. Priye, C. S. Ball, and R. J. Meagher, "Colorimetric-Luminance 
Readout for Quantitative Analysis of Fluorescence Signals with a 
Smartphone CMOS Sensor," Analytical Chemistry, vol. 90, no. 21, 
pp. 12385-12389, Nov. 2018. 
[101] L. Shen, J. A. Hagen, and I. Papautsky, "Point-of-care colorimetric 
detection with a smartphone," Lab on a Chip, 10.1039/C2LC40741H 
vol. 12, no. 21, pp. 4240-4243, Oct. 2012. 
[102] D. Xu, X. Huang, J. Guo, and X. Ma, "Automatic smartphone-based 
microfluidic biosensor system at the point of care," Biosensors and 
Bioelectronics, vol. 110, pp. 78-88, Jul. 2018. 
[103] COVID-19 SMARTPHONE TESTING KIT [Online]. Available: 
https://mobiledetectbio.com/ 
[104] D. Wu et al., "A paper-based microfluidic Dot-ELISA system with 
smartphone for the detection of influenza A," Microfluidics and 
Nanofluidics, vol. 21, no. 3, p. 43, Feb. 2017. 
[105] K. D. Long, H. Yu, and B. T. Cunningham, "Smartphone instrument 
for portable enzyme-linked immunosorbent assays," Biomedical 
optics express, vol. 5, no. 11, pp. 3792-3806, Nov. 2014. 
[106] L.-J. Wang, Y.-C. Chang, R. Sun, and L. Li, "A multichannel 
smartphone optical biosensor for high-throughput point-of-care 
diagnostics," Biosensors and Bioelectronics, vol. 87, pp. 686-692, 
Jan. 2017. 
[107] L.-J. Wang, R. Sun, T. Vasile, Y.-C. Chang, and L. Li, "High-
Throughput Optical Sensing Immunoassays on Smartphone," 
Analytical Chemistry, vol. 88, no. 16, pp. 8302-8308, Aug. 2016. 
[108] S. Rani, P. C. Biswas, M. A. Hossain, M. R. Islam, and J. Canning, 
"Polynomial regression of multiple sensing variables for high-
performance smartphone colorimeter," OSA Continuum, vol. 4, no. 2, 
pp. 374-384, Feb. 2021. 
[109] S. J. Yeo et al., "Smartphone-Based Fluorescent Diagnostic System 
for Highly Pathogenic H5N1 Viruses," Theranostics, vol. 6, no. 2, 
pp. 231-42, Jan. 2016. 
[110] A. Hossain, J. Canning, S. Ast, P. J. Rutledge, T. L. Yen, and A. 
Jamalipour, "Lab-in-a-Phone: Smartphone-Based Portable 
Fluorometer for pH Measurements of Environmental Water," IEEE 
Sensors Journal, vol. 15, no. 9, pp. 5095-5102, Sep. 2015. 
[111] M. Arafat Hossain, J. Canning, S. Ast, K. Cook, P. J. Rutledge, and 
A. Jamalipour, "Combined "dual" absorption and fluorescence 
smartphone spectrometers," Opt Lett, vol. 40, no. 8, pp. 1737-40, 
Apr. 2015. 
[112] G. Vásquez, A. Rey, C. Rivera, C. Iregui, and J. Orozco, 
"Amperometric biosensor based on a single antibody of dual function 
for rapid detection of Streptococcus agalactiae," Biosens Bioelectron, 
vol. 87, pp. 453-458, Jan. 2017. 
[113] D. Alzate, S. Cajigas, S. Robledo, C. Muskus, and J. Orozco, 
"Genosensors for differential detection of Zika virus," Talanta, vol. 
210, p. 120648, Apr. 2020. 
[114] A. Kaushik et al., "A sensitive electrochemical immunosensor for 
label-free detection of Zika-virus protein," Scientific Reports, vol. 8, 
no. 1, p. 9700, Jun. 2018. 
[115] J. T. C. Barragan and L. T. Kubota, "Minipotentiostat controlled by 
smartphone on a micropipette: A versatile, portable, agile and 
accurate tool for electroanalysis," Electrochimica Acta, vol. 341, p. 
136048, May 2020. 
[116] N. Nasir and M. Al Ahmad, "Cells Electrical Characterization: 
Dielectric Properties, Mixture, and Modeling Theories," Journal of 
Engineering, vol. 2020, p. 9475490, Jan. 2020. 
[117] P. C. Biswas, S. Rani, M. A. Hossain, M. R. Islam, and J. Canning, 
"Simultaneous Multi-Analyte Sensing Using a 2D Quad-Beam 
Diffraction Smartphone Imaging Spectrometer," Sensors and 
Actuators B: Chemical, p. 130994, 2021/10/29/ 2021. 
[118] P. C. Biswas, S. Rani, M. A. Hossain, M. R. Islam, and J. Canning, 
"Multichannel Smartphone Spectrometer Using Combined 
Diffraction Orders," IEEE Sensors Letters, vol. 4, no. 9, pp. 1-4, 
2020. 
[119] G. Qiu, Z. Gai, Y. Tao, J. Schmitt, G. A. Kullak-Ublick, and J. 
Wang, "Dual-Functional Plasmonic Photothermal Biosensors for 
Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 
Detection," ACS Nano, vol. 14, no. 5, pp. 5268-5277, May 2020. 
[120] J. Lu et al., "Immunoassay for Detection of Infliximab in Whole 
Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor," 
Analytical Chemistry, vol. 89, no. 6, pp. 3664-3671, Mar. 2017. 
[121] C. Han, J. Canning, K. Cook, M. A. Hossain, and H. Ding, "Exciting 
surface plasmons on metal-coated multimode optical waveguides 
using skew rays," Optics Letters, vol. 41, no. 22, pp. 5353-5356, 
2016/11/15 2016. 
[122] J. Canning, M. A. Hossain, C. Han, L. Chartier, K. Cook, and T. 
Athanaze, "Drawing optical fibers from three-dimensional printers," 
Opt Lett, vol. 41, no. 23, pp. 5551-5554, Dec. 2016. 
[123] K. Cook et al., "Air-structured optical fiber drawn from a 3D-printed 
preform," Opt Lett, vol. 40, no. 17, pp. 3966-9, Sep. 2015. 
[124] J. Canning, "Fibre gratings and devices for sensors and lasers," Laser 
& Photonics Reviews, https://doi.org/10.1002/lpor.200810010 vol. 2, 
no. 4, pp. 275-289, Aug. 2008. 
[125] D. Wrapp et al., "Cryo-EM structure of the 2019-nCoV spike in the 
prefusion conformation," Science, vol. 367, no. 6483, p. 1260, Mar. 
2020. 
[126] B. Shmuel, C. Meir, M. Michael, R. Shira, and D. Amos, 
"Magnetically aggregated biosensors for sensitive detection of 
biomarkers at low concentrations (Conference Presentation)," in 
Proc.SPIE, 2020, vol. 11258. 
[127] New technology may significantly reduce diagnostic time of 
coronavirus [Online]. Available: 
https://www.eurekalert.org/pub_releases/2020-02/bu-ntm021420.php 
[128] W. Yang and F. Yan, "Patients with RT-PCR-confirmed COVID-19 
and Normal Chest CT," Radiology, vol. 295, no. 2, p. E3, May 2020. 
[129] M. Jamshidi et al., "Artificial Intelligence and COVID-19: Deep 
Learning Approaches for Diagnosis and Treatment," IEEE Access, 
vol. 8, pp. 109581-109595, 2020. 
[130] R. Schirhagl, K. Chang, M. Loretz, and C. L. Degen, "Nitrogen-
Vacancy Centers in Diamond: Nanoscale Sensors for Physics and 
          M. A. Hossain et al: Rapid Testing & Bioinformatic Analysis of SARS-CoV-2 and Human Respiratory Viruses in Pandemics 
19 
 
Biology," Annual Review of Physical Chemistry, vol. 65, no. 1, pp. 
83-105, 2014/04/01 2014. 
[131] M. Naqshbandi, J. Canning, B. C. Gibson, M. M. Nash, and M. J. 
Crossley, "Room temperature self-assembly of mixed nanoparticles 
into photonic structures," Nature Communications, vol. 3, no. 1, p. 
1188, 2012/11/13 2012. 
[132] B. Shi, Y. Li, D. Wu, and W. Wu, "A handheld continuous-flow real-
time fluorescence qPCR system with a PVC microreactor," Analyst, 
10.1039/C9AN01894H vol. 145, no. 7, pp. 2767-2773, Apr. 2020. 
[133] T. Gou et al., "Smartphone-based mobile digital PCR device for 
DNA quantitative analysis with high accuracy," Biosensors and 
Bioelectronics, vol. 120, pp. 144-152, Nov. 2018. 
[134] C. D. Ahrberg, B. R. Ilic, A. Manz, and P. Neužil, "Handheld real-
time PCR device," Lab on a Chip, 10.1039/C5LC01415H vol. 16, 
no. 3, pp. 586-592, Feb. 2016. 
[135] T. Laksanasopin et al., "A smartphone dongle for diagnosis of 
infectious diseases at the point of care," Sci Transl Med, vol. 7, no. 
273, p. 273re1, Feb. 2015. 
[136] M. K. Kanakasabapathy et al., "Rapid, label-free CD4 testing using a 
smartphone compatible device," Lab Chip, vol. 17, no. 17, pp. 2910-
2919, Aug. 2017. 
[137] E. Costa, E. Climent, S. Ast, M. G. Weller, J. Canning, and K. 
Rurack, "Development of a lateral flow test for rapid pyrethroid 
detection using antibody-gated indicator-releasing hybrid materials," 
Analyst, 10.1039/D0AN00319K vol. 145, no. 10, pp. 3490-3494, 
May 2020. 
[138] R. Campos et al., "Attomolar Label-Free Detection of DNA 
Hybridization with Electrolyte-Gated Graphene Field-Effect 
Transistors," ACS Sensors, vol. 4, no. 2, pp. 286-293, Feb. 2019. 
[139] M. T. Hwang et al., "Ultrasensitive detection of nucleic acids using 
deformed graphene channel field effect biosensors," Nature 
Communications, vol. 11, no. 1, p. 1543, Mar. 2020. 
[140] V. C. Martins et al., "Femtomolar limit of detection with a 
magnetoresistive biochip," Biosens Bioelectron, vol. 24, no. 8, pp. 
2690-5, Apr. 2009. 
[141] B. Ibarlucea et al., "Ultrasensitive detection of Ebola matrix protein 
in a memristor mode," Nano Research, vol. 11, no. 2, pp. 1057-1068, 
Feb. 2018. 
[142] CONVAT project aims for point-of-care Covid-19 diagnosis 
[Online]. Available: https://optics.org/news/11/4/13 
[143] X. Mei et al., "Artificial intelligence–enabled rapid diagnosis of 
patients with COVID-19," Nature Medicine, vol. 26, no. 8, pp. 1224-
1228, Aug. 2020. 
[144] X. Tian et al., "Potent binding of 2019 novel coronavirus spike 
protein by a SARS coronavirus-specific human monoclonal 
antibody," Emerging microbes & infections, vol. 9, no. 1, pp. 382-
385, Feb. 2020. 
[145] J. Canning, M. Ma, B. C. Gibson, J. Shi, K. Cook, and M. J. 
Crossley, "Highly ordered mesoporous silica microfibres produced 
by evaporative self-assembly and fracturing," Optical Materials 
Express, vol. 3, no. 12, pp. 2028-2036, 2013/12/01 2013. 
[146] Y. Yamada et al., "Nanofabrication of a Solid-State, Mesoporous 
Nanoparticle Composite for Efficient Photocatalytic Hydrogen 
Generation," ChemPlusChem, 
https://doi.org/10.1002/cplu.201600148 vol. 81, no. 6, pp. 521-525, 
2016/06/01 2016. 
[147] J. R. Sempionatto et al., "An epidermal patch for the simultaneous 
monitoring of haemodynamic and metabolic biomarkers," Nature 
Biomedical Engineering, vol. 5, no. 7, pp. 737-748, 2021/07/01 
2021. 
[148] L. Wang, Z. Lou, K. Jiang, and G. Shen, "Bio-Multifunctional Smart 
Wearable Sensors for Medical Devices," Advanced Intelligent 
Systems, https://doi.org/10.1002/aisy.201900040 vol. 1, no. 5, p. 
1900040, 2019/09/01 2019. 
[149] Sensors woven into a shirt can monitor Covid-19 signs: MIT 
[Online]. Available: http://textilefocus.com/sensors-woven-shirt-can-
monitor-covid-19-signs-mit/ 
[150] A. J. Galante, S. Haghanifar, E. G. Romanowski, R. M. Q. Shanks, 
and P. W. Leu, "Superhemophobic and Antivirofouling Coating for 
Mechanically Durable and Wash-Stable Medical Textiles," ACS 
Applied Materials & Interfaces, vol. 12, no. 19, pp. 22120-22128, 
May 2020. 
[151] H. I. s. writers. (2020, 30 Nov 2020). Treated Fabric with Antiviral 




[152] N. M. Ferguson, D. A. T. Cummings, C. Fraser, J. C. Cajka, P. C. 
Cooley, and D. S. Burke, "Strategies for mitigating an influenza 
pandemic," Nature, vol. 442, no. 7101, pp. 448-452, Jul. 2006. 
[153] S. Tabik et al., "COVIDGR Dataset and COVID-SDNet 
Methodology for Predicting COVID-19 Based on Chest X-Ray 
Images," IEEE Journal of Biomedical and Health Informatics, vol. 
24, no. 12, pp. 3595-3605, 2020. 
[154] L. Fan et al., "Progress and prospect on imaging diagnosis of 
COVID-19," Chinese Journal of Academic Radiology, vol. 3, no. 1, 
pp. 4-13, Mar. 2020. 
[155] R. Bennett and A. French, "Rise of the smart device ECG and what it 
means for the general cardiologist," Heart, vol. 105, no. 22, p. 1763, 
Nov. 2019. 
[156] WHO, "Increasing access to diagnostics through technology transfer 
and local production," 2011 2011, Available: 
https://www.who.int/phi/publications/Increasing_Access_to_Diagnos












Md Arafat Hossain (M’2014–) Md Arafat 
Hossain received a Ph.D. degree in 2017 on 
smart sensing and instrumentation from The University of Sydney, 
Australia, where he worked with Prof. John Canning. He is currently an 
Associate Professor of electrical and electronic engineering with the 
Khulna University of Engineering & Technology, Khulna, Bangladesh. 
His research interests include smart sensing, smartphone instrumentations, 
and 3D-printed optics. He was the recipient of 
the Australian Award of Endeavour 
Fellowship for his postdoctoral research at The 
University of Sydney. 
 
 
Barbara Brito-Rodriguez is a Chancellor's 
Postdoctoral Fellow at The i3 Institute of The 
University of Technology Sydney, Sydney, 
Australia. Previously she worked as a Post-
Doctoral Fellow at the Oak Ridge Institute for Science and Education in 
United States Department of Agriculture, Plum Island Animal Disease 
Center, Agricultural Research Services (USA). She received a PhD in 
Epidemiology from the University of 
California (USA) in 2015. 
 
 
Lisa M Sedger is the heads of the Viruses 
and Cytokine Biology group in the School of 
Life Science at UTS. Lisa gained her 
B.App.Science degree with First Class 
Honours in immunology in Prof Raison's 
laboratory at UTS. She completed a PhD 
(1995) in viral immunology and virus host-
interactions at the John Curtin School of Medical Research, Australian 
National University (ANU). Dr Sedger undertook post-doctoral training 
internationally. She was awarded an Alberta Heritage Foundation Post-
Doctoral Fellowship to work in Prof. McFadden Viral Pathogenesis 
Laboratory in the Dept. Biochemistry at the University of Alberta, 
Edmonton, Canada (1995-1997). She then undertook a Post-Doctoral 
position in Molecular Immunology at Immunex Corporation (now Amgen) 
in Seattle, USA (1997-2000). Her post-doctoral research focused on viral 
          M. A. Hossain et al: Rapid Testing & Bioinformatic Analysis of SARS-CoV-2 and Human Respiratory Viruses in Pandemics 
20 
 
modulators of Tumour Necrosis Factor (TNF) (University of Alberta), and 
the immunobiology of the TNF-family cytokines (Immunex Corporation). 
Dr Sedger joined the USyd as a U2000 Fellow based primarily at the 
Westmead Millennium Institute (2000-2007). She is now Senior Lecturer 
(Virology) in the Faculty of Science, UTS, where she lectures in Virology, 
Immunology and Flow Cytometry. Dr Sedger research is focused on virus-
host interactions and cytokines, including basic biology, 
immunopathology, and immune profiling in infection and immune-based 
disease conditions. Dr Sedger research is highly cited (she has a career 
citation rate of >4890 - according to Google Scholar, Jan 2021). 
 
 
John Canning is a Professor of the School of 
Electrical and Data Engineering of University of 
Technology Sydney (UTS), Australia. He 
received the Ph.D. degree from The University of 
Sydney in 1996. He is the Head of the 
interdisciplinary Photonics Laboratories (iPL) 
and a member of the Global Big Data 
Technologies Centre (GBDTC) with the UTS, a 
Conjoint Professor with the National Fibre 
Facility, UNSW, and an Honorary Professor with the University of 
Sydney. He has published 850 peer-reviewed journals and conference 
papers and holds over 40 patents spanning communications, materials, 
devices, lasers and processing. He has been a cofounder and an advisor of 
several start-ups. He is a Fellow of SPIE and OSA and was a recipient of 
the 2017 OSA David Richardson Medal. 
